On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize malaria as a major global health threat, with approximately 250 million cases and over 600,000 deaths annually, disproportionately affecting children under five and pregnant women in sub-Saharan Africa.
- •Identify the five primary human pathogens: (most virulent), P. vivax (common in Asia/Americas, forms dormant liver stages), P. ovale (also forms liver stages), P. malariae (72-hour cycle), and P. knowlesi (zoonotic, 24-hour cycle).
- •Understand the life cycle involving the female mosquito vector, which injects sporozoites that first infect the liver (exo-erythrocytic cycle) before entering the bloodstream to infect red blood cells (erythrocytic cycle).
- •Note the emergence of artemisinin partial resistance (ART-R), particularly in Southeast Asia and parts of Africa, characterized by delayed parasite clearance and mutations in the pfk13 gene.
- •Consider host genetic factors that influence disease course, such as (risk of hemolysis with certain drugs), the Duffy-negative phenotype (historically protective against P. vivax), and sickle cell trait (protective against severe P. falciparum).
Evaluation
- •Suspect malaria in any patient with an unexplained fever who has lived in or traveled to an endemic region within the last year, even if they took chemoprophylaxis.
- •Ask about the pattern of fever paroxysms (chills, high fever, and sweating), though classic 48- or 72-hour cycles are often absent in the early stages or in non-immune individuals.
- •Examine for signs of severe disease, including altered mental status (cerebral malaria), respiratory distress (acidotic breathing), jaundice, and spontaneous bleeding or petechiae.
- •Order immediate parasitological testing with thick and thin blood smears; the thick smear is used for screening (sensitivity 50–100 parasites/µL), while the thin smear is used for species identification and quantification.
- •Utilize Rapid Diagnostic Tests (RDTs) for Histidine-Rich Protein 2 (HRP2) or parasite Lactate Dehydrogenase (pLDH) when microscopy is unavailable, but be aware of false negatives in HRP2-deleted strains.
- •Repeat blood smears every 6–12 hours for 48 hours if the initial test is negative but clinical suspicion remains high, as parasitemia can fluctuate significantly.
- •Screen for red flags of severe malaria: Glasgow Coma Scale (GCS) < 11, hemoglobin < 7 g/dL, serum creatinine > 3 mg/dL, or blood glucose < 40 mg/dL.
- •Perform pulse oximetry on all patients; an SpO2 < 90% is a high-risk marker for mortality and indicates the need for urgent respiratory support.
- •Evaluate for (CM) by assessing consciousness using the Blantyre Coma Scale in children or GCS in adults; CM is defined by a GCS < 11 persisting for >1 hour after a seizure.
- •Obtain a complete blood count (CBC) to assess for thrombocytopenia and anemia, and a metabolic panel to monitor for acute kidney injury (MAKI) and hypoglycemia.
- •Rule out other tropical febrile illnesses such as , , and , which often present with overlapping symptoms.
- •Test for using a point-of-care biosensor before initiating radical cure therapy for P. vivax or P. ovale to prevent life-threatening hemolysis.
Management
- •Administer intravenous (IV) 2.4 mg/kg at 0, 12, and 24 hours for all cases of severe malaria, regardless of the infecting species.
- •Transition to a full 3-day course of oral Artemisinin-based Combination Therapy (ACT) once the patient with severe malaria can tolerate oral intake.
- •Treat uncomplicated P. falciparum with oral Artemether-lumefantrine (20/120 mg tablets, weight-based dosing twice daily for 3 days) as the first-line regimen.
- •Use Dihydroartemisinin-piperaquine as an alternative ACT in regions with documented resistance to artemether-lumefantrine.
- •Provide radical cure for P. vivax and P. ovale by administering Primaquine 0.25–0.5 mg/kg daily for 14 days to eliminate latent liver hypnozoites.
- •Ensure G6PD activity is >30% before giving primaquine; in patients with intermediate deficiency (30-70% activity), consider weekly primaquine (0.75 mg/kg) for 8 weeks under close supervision.
- •Manage hypoglycemia aggressively with IV Dextrose (e.g., 10% dextrose 5 mL/kg in children) and monitor blood glucose every 4 hours, as quinine and the infection itself can cause profound drops.
- •Control seizures with IV Diazepam 0.3 mg/kg or Midazolam 0.1 mg/kg; if seizures recur, escalate to Phenobarbital 20 mg/kg IV.
- •Maintain fluid homeostasis using balanced crystalloids (Lactated Ringer's) at 3-4 mL/kg/hr, but avoid aggressive fluid boluses in cerebral malaria unless the patient is in shock to prevent cerebral edema.
- •Monitor for delayed post-artesunate hemolysis (PADH), which can occur 1–3 weeks after treatment with IV artesunate, particularly in patients with high initial parasitemia.
- •Avoid using artemisinin monotherapy, as this rapidly drives the development of drug resistance.
- •Refer all pregnant women with malaria for specialist obstetric and infectious disease consultation, as they are at high risk for severe anemia and placental sequestration.
- •Implement Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) in children aged 3–59 months in high-transmission seasonal areas.
- •Recommend the R21/Matrix-M or RTS,S/AS01 vaccine for children in endemic regions as part of a multi-tiered prevention strategy.
- •Discharge patients only after they have completed at least 24 hours of oral therapy, are afebrile, have a declining parasite count, and can tolerate oral medications and fluids.
Board Review — High Yield
- •Cerebral malaria — Defined by GCS < 11 or Blantyre ≤ 2 in the presence of P. falciparum parasitemia.
- •Blackwater fever — Severe intravascular hemolysis leading to hemoglobinuria (dark urine), often associated with P. falciparum.
- •Schüffner dots — Fine stippling seen in red blood cells infected with P. vivax or P. ovale.
- •Banana-shaped gametocytes — Pathognomonic microscopic finding for P. falciparum.
- •Hypnozoites — Dormant liver stages of P. vivax and P. ovale responsible for clinical relapses months later.
- •Maurer clefts — Membranous sacs seen in P. falciparum-infected erythrocytes used for protein transport.
- •Duffy Antigen — The receptor required for P. vivax entry; Duffy-negative individuals (common in West Africa) are largely resistant.
- •Sequestration — P. falciparum cytoadherence to vascular endothelium via PfEMP1, causing microvascular obstruction.
- •Recrudescence — Reappearance of parasitemia from the blood cycle (due to treatment failure), distinct from relapse (from liver).
Deep Dive — Evidence Details
Definition, Synonyms, and Classification of Malaria
- ▸Malaria is caused by Apicomplexan parasites of the genus Plasmodium, transmitted by Anopheles mosquitoes [1, 3].
- ▸Five main species infect humans: P. falciparum, P. vivax, P. ovale, P. malariae, and the zoonotic P. knowlesi [2, 7, 16].
- ▸Clinical classification distinguishes between uncomplicated malaria and severe malaria, the latter involving organ dysfunction such as cerebral malaria [6].
Malaria is an acute and potentially life-threatening febrile illness caused by obligate intracellular protozoan parasites of the genus , which are transmitted to humans through the bites of infected female mosquitoes [1]D[3]D[10]D. These parasites belong to the phylum Apicomplexa, a diverse group of microbes that evolved from phototrophic ancestors to become specialized symbionts [1]D. In humans, the disease is characterized by periodic paroxysms of chills, fever, and sweating, often accompanied by anemia and splenomegaly [18]D. While primarily a human disease, various species infect a wide range of hosts, including non-human primates, birds, and reptiles [11]D[12]D[20]D.
Synonyms and Alternate Names
Historically and across different clinical contexts, malaria has been referred to by several names:
- Ague: An archaic term for the shivering fits or malarial chill.
- Marsh Fever: A historical name reflecting the association between stagnant water (mosquito breeding sites) and disease transmission.
- Quartan Malaria: Specifically refers to the 72-hour cycle of fever paroxysms characteristic of P. malariae [2]D.
- Tertian Malaria: Refers to the 48-hour cycle of fever seen in P. falciparum, P. vivax, and P. ovale.
- Paludism: Derived from the Latin palus (marsh), commonly used in French and Spanish medical literature.
- Zoonotic Malaria: Specifically refers to infections transmitted from animals to humans, most notably P. knowlesi [7]D.
Clinical Phases and Definitions
To standardize the description of malaria's clinical course, the following terms are utilized to define the stages of infection and recovery:
- Prodromal Phase: The initial period following the incubation period (which varies by species) where the patient experiences non-specific symptoms such as headache, malaise, and myalgia before the onset of classic paroxysms [18]D.
- Progressive Phase: The stage characterized by an increasing parasite burden in the blood (erythrocytic cycle), leading to escalating clinical severity and the potential development of complications such as severe anemia or organ dysfunction [9]D.
- Nadir: In the context of malaria, this typically refers to the lowest point of hematologic parameters, particularly hemoglobin levels or platelet counts, which often occurs during or immediately after the peak of parasitemia.
- Plateau: A period where the clinical symptoms and parasite density stabilize, often seen in semi-immune individuals or during the early stages of effective treatment.
- Recovery Phase: The period following the clearance of parasites from the peripheral blood, characterized by the resolution of symptoms and the restoration of normal physiologic function.
- Nadir of Parasitemia: The point at which parasites are no longer detectable by microscopy or PCR following successful intervention [19]D.
Classification of Plasmodium Species
Human malaria is caused by five primary species of the genus . Classification is based on morphological characteristics, the length of the erythrocytic cycle, and clinical virulence. Recent genomic evidence has also identified specific adaptations, such as the ability of P. vivax to infect Duffy-negative individuals in sub-Saharan Africa, a population previously thought to be resistant [16]D.
Classification by Clinical Severity
Malaria is clinically categorized into two major forms to guide protocols:
- Uncomplicated Malaria: Symptomatic infection with a low parasite density and no evidence of vital organ dysfunction. Symptoms often overlap with other tropical febrile illnesses like Zika or Oropouche virus [15]D[18]D.
- Severe Malaria: Defined by the presence of one or more of the following: cerebral malaria (characterized by CXCL10high microglia driving neuroinflammation [6]D), severe anemia, acute kidney injury, or pulmonary edema.
Vector Classification
Transmission is dependent on mosquitoes of the genus. These are often classified into species complexes, which are groups of morphologically identical but genetically distinct cryptic species [3]D[5]D. For example, the Anopheles cruzii complex in the Brazilian Atlantic Forest consists of at least five cryptic species (A-E) [3]D. Identifying these complexes is critical because different members may have varying host-seeking behaviors, such as a preference for human versus animal hosts [14]D.
| Species | Common Name | Erythrocytic Cycle | Key Distinguishing Features |
|---|---|---|---|
| P. falciparum | Malignant tertian | 48 hours | Highest virulence; responsible for most deaths; associated with k13 mutations and artemisinin resistance [9]D[19]D. |
| P. vivax | Benign tertian | 48 hours | Forms hypnozoites (latent liver stage); increasingly found in Duffy-negative African populations [16]D. |
| P. malariae | Quartan malaria | 72 hours | Longest cycle; generally lower parasitemia and milder symptoms [2]D. |
| P. ovale | Ovale tertian | 48 hours | Similar to P. vivax; also forms hypnozoites; primarily found in sub-Saharan Africa. |
| P. knowlesi | Zoonotic malaria | 24 hours | Primarily infects long-tailed macaques; can cause severe disease in humans due to rapid 24-hour cycle [7]D. |
Epidemiology and Risk Factors
- ▸Sub-Saharan Africa accounts for the majority of the 241-249 million annual malaria cases, with Nigeria bearing the highest burden [26, 36].
- ▸Host genetic factors, including G6PD deficiency and Duffy antigen status, are critical determinants of species-specific susceptibility and treatment safety [23, 47].
- ▸Environmental factors such as housing quality and climate variability significantly modulate transmission risk and the effectiveness of vector control interventions [30, 31].
Malaria remains one of the most significant global health threats, with an estimated 241 to 249 million cases and over 600,000 deaths occurring annually [26]. The burden is disproportionately distributed, with sub-Saharan Africa (SSA) bearing the highest morbidity and mortality rates, particularly among vulnerable populations such as children under five and pregnant women [36]D[44]D. While some regions, such as China, have achieved significant reductions in incidence to approximately 5.599 per 100,000 [29]D, other areas face challenges from imported cases and shifting environmental drivers [25][30]D.
Geographic Distribution and Endemicity
The of malaria is defined by the presence of competent vectors and suitable environmental conditions for parasite development.
- Sub-Saharan Africa: This region accounts for the vast majority of the global burden. Nigeria consistently reports the highest population burden of [36]D. In Eastern Sub-Saharan Africa (ESSA), malaria remains a leading cause of fatal and non-fatal health outcomes among women of reproductive age (WRA) [44]D.
- Asia-Pacific: Countries in this region are largely in the elimination phase, but progress is hampered by imported malaria. A meta-analysis of 22 Asia-Pacific countries identified imported cases as a major barrier to sustaining elimination [25]. In Indonesia, the prevalence of is a significant concern, complicated by high rates of [23].
- The Americas: Transmission is concentrated in the Amazon basin. In Brazil, the risk of P. vivax relapse is closely linked to host genetic factors, specifically cytochrome P-450 (CYP) 2D6 activity, which is required to metabolize [27].
Demographic Risk Factors
Age and Immunity
Children under the age of five are at the highest risk for severe malaria and death due to a lack of acquired immunity. In Nigeria, malaria and soil-transmitted helminth (STH) coinfections are common in this age group, significantly altering hematological parameters and increasing the risk of anemia [46]D. Conversely, in high-transmission settings, adults often develop partial immunity, leading to a high prevalence of asymptomatic infections that serve as a persistent reservoir for transmission [32]D.
Pregnancy
Pregnant women are a high-risk group because the physiological changes of pregnancy and the sequestration of parasites in the placenta increase the risk of severe maternal anemia and adverse birth outcomes [34]D[44]D. Intermittent preventive treatment in pregnancy (IPTp) with (0.5 g/0.025 g, 3 doses) is a standard intervention, yet coverage remains suboptimal in many regions, such as Madagascar and Nigeria, due to missed opportunities during antenatal care visits [34]D[49]D.
Genetic and Biological Risk Factors
Host genetics play a critical role in determining susceptibility to specific Plasmodium species and the safety of treatments.
- Duffy Antigen Receptor for Chemokines (DARC): The interaction between the Duffy-binding protein (PvDBP) and DARC is the primary mechanism for P. vivax entry into red blood cells. In Ethiopia, genetic variations in the Duffy blood group significantly influence susceptibility to P. vivax malaria [47]D.
- G6PD Deficiency: This X-linked genetic disorder is prevalent in malaria-endemic regions like Indonesia [23]. It is a critical risk factor because the administration of (0.25 mg/kg/day for 14 days) can trigger life-threatening in deficient individuals [23].
- CYP2D6 Activity: Reduced activity of the CYP2D6 enzyme (Activity Score < 1.0) is associated with an increased risk of P. vivax relapse, as the enzyme is necessary for the bioactivation of primaquine into its active metabolites [27].
Environmental and Socioeconomic Drivers
Climate and Seasonality
Malaria transmission is highly climate-sensitive. In Bangladesh, spatiotemporal patterns are driven by temperature, relative humidity, and precipitation, which influence vector breeding cycles [30]D. In South Africa, climatic extremes and migration flows from neighboring endemic countries interact to shape local risk patterns, necessitating adaptive surveillance [37]D.
Housing and Prevention Tools
Housing quality is a major determinant of risk. Improved floor, wall, and roof materials reduce the entry of mosquitoes into the home. In The Gambia, the combination of improved housing and the use of insecticide-treated nets (ITNs) is significantly associated with a reduction in childhood anemia [31]D. However, the effectiveness of ITNs can be undermined by poor utilization rates and the emergence of insecticide resistance [48]D.
Protocol for Epidemiological Risk Stratification
Clinicians and public health officials should follow these steps to assess population-level risk in endemic or elimination-phase settings:
- Step 1: Identify Ecological Archetypes. Determine the local transmission intensity based on ecological drivers (e.g., forest-based exposure vs. urban informal settlements) [37]D[45]D.
- Step 2: Screen for Genetic Vulnerabilities. In regions where P. vivax is prevalent, implement G6PD screening before administering high-dose primaquine regimens (1 mg/kg/day for 7 days) to prevent hemolytic crises [23].
- Step 3: Monitor Coinfection Prevalence. In SSA, assess for coinfections with Schistosoma species or STHs, as these can exacerbate malaria-related anemia [24][46]D.
- Step 4: Evaluate Intervention Coverage. Audit the uptake of IPTp-SP in pregnant women and ITN utilization in households to identify gaps in protection [34]D[48]D.
| Risk Factor | Association/Impact | Evidence Level |
|---|---|---|
| Age < 5 years | Highest risk for severe malaria and mortality due to low immunity | 2a [26][46]D |
| Pregnancy | Increased risk of severe anemia and placental sequestration | 5 [34]D[44]D |
| G6PD Deficiency | High risk of hemolysis when treated with primaquine | 2a [23] |
| Duffy Negative Phenotype | Protective against P. vivax infection | 5 [47]D |
| Reduced CYP2D6 Activity | Increased risk of P. vivax relapse due to poor primaquine metabolism | 2b [27] |
| Poor Housing Quality | Increased vector exposure and higher risk of childhood anemia | 5 [31]D |
| Schistosoma Coinfection | Potential exacerbation of malaria morbidity in children | 2a [24] |
History and Physical Examination
- ▸Malaria accounts for approximately 20% of acute febrile illness cases in endemic regions, but its symptoms overlap significantly with dengue and other tropical fevers.
- ▸Critical physical findings include splenomegaly, jaundice, and respiratory distress, with SpO2 < 90% serving as a key threshold for severe disease.
- ▸Atypical presentations, such as reversible paralysis in pregnancy or undifferentiated fever in older travelers, require a high index of suspicion and detailed travel history.
The clinical presentation of malaria is notoriously non-specific, often mimicking other causes of (AFI). In malaria-endemic regions, the pooled prevalence of malaria among patients presenting with undifferentiated fever is approximately 20.2% [53]. Because symptoms overlap significantly with other tropical pathogens—including (15.0%), Influenza (5.4%), and (3.3%)—a meticulous history and physical examination are essential to differentiate malaria from other life-threatening etiologies [53].
Presenting Symptoms
The hallmark of malaria is an intermittent fever, which may persist for over a week before the patient seeks tertiary care [57]C. While classic paroxysms (sequential cold, hot, and sweating stages) are traditionally described, many patients present with a more undifferentiated prodrome. Common symptoms include headache, loss of appetite, and vomiting [57]C. In pediatric populations, caregivers often report a history of fever within the past week, even if the child is afebrile at the time of the encounter [62]D.
In certain regions, such as Southeast Asia, clinicians must maintain a high index of suspicion for zoonotic malaria caused by Plasmodium knowlesi, which has emerged in areas previously nearing elimination of human-only species [59]D. Symptoms in these cases are often indistinguishable from other Plasmodium infections but may carry a higher risk of rapid progression [59]D.
Neurological and Physical Examination Findings
A systematic physical examination is critical for identifying severe malaria and assessing for complications.
- General Appearance: Patients often appear acutely ill. Jaundice and mucosal bleeding may be present, particularly in outbreaks where malaria is suspected alongside viral hemorrhagic fevers [4]D.
- Neurological System: While cerebral malaria is the most feared neurological complication, atypical presentations such as reversible paralysis have been documented, particularly in pregnant patients [56]C. Clinicians should assess for neck pain, which may mimic meningitis, and perform a full motor and sensory exam to rule out spinal or peripheral nerve involvement [56]C.
- Abdominal Findings: Splenomegaly and hepatomegaly are common due to the sequestration of parasitized erythrocytes and reactive lymphoid hyperplasia. Abdominal pain is a frequent complaint and may be severe enough to mimic an acute abdomen [4]D[56]C.
- Respiratory System: Respiratory distress is a major predictor of mortality. The use of routine is recommended; an SpO2 < 90% indicates severe hypoxemia and requires urgent intervention [69]D.
Phenotypic Variants and Species Differences
While P. falciparum is responsible for the majority of severe cases, non-falciparum species are frequently underestimated and may be missed by standard rapid diagnostic tests (RDTs) [60]D.
| Variant | Key Features | Frequency/Context |
|---|---|---|
| P. falciparum | High parasite density, risk of cerebral malaria, severe anemia [60]D | Dominant in sub-Saharan Africa |
| Non-falciparum | Often lower parasite density; includes P. vivax, P. ovale, P. malariae [60]D | Up to 70% of cases in some West African cohorts |
| P. knowlesi | Zoonotic (macaque host), rapid 24-hour erythrocytic cycle [59]D | Emerging in Southeast Asia |
| Placental Malaria | Sequestration in the placenta; leads to low birth weight and stunting [64]D | Pregnant women in endemic areas |
Red Flags
Certain clinical signs necessitate immediate escalation of care and consideration for parenteral therapy. These include:
- Respiratory Compromise: SpO2 < 90% or clinical signs of respiratory distress (tachypnea, accessory muscle use) [69]D.
- Neurological Impairment: Altered consciousness, seizures, or focal neurological deficits like paralysis [56]C.
- Hematological Instability: Spontaneous mucosal bleeding or profound jaundice [4]D.
- Vulnerable Populations: Children under 5 years of age and pregnant women are at the highest risk for rapid deterioration [52][56]C[76]D.
Atypical Presentations and Diagnostic Challenges
Malaria may be missed in travelers returning from endemic regions to low-endemicity areas, where routine testing is not standard [57]C. In older travelers (age > 60), physiological changes and comorbidities can mask typical symptoms, leading to delayed diagnosis [63]D. Furthermore, co-infections are common; in Nigeria, patients with malaria are frequently co-infected with other epidemic-prone pathogens, which can alter the clinical phenotype and complicate the diagnostic process [73]D[79]D.
Physical Examination Protocol
Step 1: Vital Signs and Triage → Measure temperature, heart rate, and blood pressure. Crucial: Perform pulse oximetry on all febrile children; SpO2 < 90% is a high-risk marker for 14-day mortality [69]D. Step 2: Neurological Assessment → Evaluate the Glasgow Coma Scale (GCS) or Blantyre Coma Scale. Check for neck stiffness and focal motor deficits [56]C. Step 3: Abdominal Palpation → Assess for splenomegaly and hepatomegaly. Note any localized tenderness that might suggest a secondary bacterial infection or splenic rupture. Step 4: Skin and Mucosa → Inspect for jaundice, pallor (suggesting severe anemia), and petechiae or mucosal bleeding [4]D. Step 5: Nutritional Status → In children, assess for linear growth faltering or stunting, as chronic malaria and malnutrition (MAM) often coexist in endemic regions [51][64]D.
| Pathogen | Pooled Prevalence | Distinguishing Features |
|---|---|---|
| Malaria (Plasmodium spp.) | 20.2% | Intermittent fever, splenomegaly, anemia [53] |
| Dengue Virus (DENV) | 15.0% | Retro-orbital pain, rash, leukopenia [53][61]D |
| Influenza | 5.4% | Prominent respiratory symptoms, cough [53] |
| Hepatitis | 3.3% | Jaundice, right upper quadrant pain [53] |
| Chikungunya (CHIKV) | 1.5% | Severe arthralgia, polyarthritis [53][61]D |
Clinical Features and Variants
- ▸Severe malaria is a multi-system emergency characterized by cerebral involvement, severe anemia (Hb < 5 g/dL), and acute kidney injury.
- ▸P. vivax is no longer considered 'benign' and can cause severe complications including ARDS and MAKI similar to P. falciparum.
- ▸Hypoglycemia (glucose < 40 mg/dL) and metabolic acidosis are critical predictors of pediatric mortality.
Malaria presents as a broad clinical spectrum, ranging from asymptomatic parasitemia to life-threatening multi-organ failure [87]D. The clinical course is driven by extensive , systemic inflammation, and oxidative stress, often modulated by host factors such as heme oxygenase-1 (HO-1) expression [87]D. While historically categorized by species-specific patterns, recent evidence emphasizes that both Plasmodium falciparum and Plasmodium vivax can result in severe, fatal complications [81][104]D.
Presenting Symptoms
The hallmark of malaria is an acute febrile illness. In endemic regions, the transition from uncomplicated to severe malaria can be rapid, particularly in children where delays in seeking care (ranging from 2% to 95.8% of cases) significantly increase mortality risk [80][82].
- Initial Phase: Patients typically present with non-specific "flu-like" symptoms, including high-grade fever, chills, rigors, headache, and myalgia [85].
- Progression: If untreated, symptoms may progress over hours to days. In children, the progression to severe malaria is a proxy for naturally acquired immunity; those with lower immunity transition faster to life-threatening states [82].
- Involvement: Nausea, vomiting, and abdominal pain are common, often leading to dehydration and complicating oral therapy [99]D.
Neurological Examination Findings
Neurological involvement, specifically (CM), is a primary driver of mortality in P. falciparum infections [83]. A structured neurological assessment is essential for every suspected case.
Protocol: Neurological Assessment for Severe Malaria
- Assess Consciousness: Use the Blantyre Coma Scale (children) or Glasgow Coma Scale (adults). CM is defined by a GCS < 11 or BCS ≤ 2 persisting for >1 hour after a seizure [83].
- Evaluate Brainstem Function: Check pupillary light reflex, oculocephalic reflex, and respiratory patterns. Abnormalities may indicate impending herniation [42]D.
- Motor and Reflex Testing: Assess for decorticate or decerebrate posturing, which suggests severe cortical or brainstem dysfunction. Hyperreflexia and extensor plantar responses are common [90].
- Seizure Monitoring: Identify both overt generalized tonic-clonic seizures and subtle status epilepticus (e.g., eye deviation, twitching) [83].
Long-term neurological sequelae, termed gross neurologic deficits (GNDs), occur in approximately 10% of pediatric survivors and include hemiplegia, ataxia, blindness, and speech impairments [90].
Phenotypic Variants
Malaria manifestations vary significantly by species and host physiological state (e.g., pregnancy).
| Variant | Key Features | Frequency/Context |
|---|---|---|
| Severe Falciparum | Hyperparasitemia, cerebral malaria, severe anemia (Hb < 5 g/dL), and AKI [84][93]D. | Most common cause of malaria death globally. |
| Severe Vivax | Jaundice, ARDS, and acute kidney injury; previously considered "benign" [81][85]. | Increasing prevalence in South Asia and South America [92]C. |
| Placental Malaria | Parasite cytoadherence in the placenta via VAR2CSA; causes low birth weight and maternal anemia [95]D. | Specific to pregnant women in endemic areas. |
| Quartan Malaria | Caused by P. malariae; characterized by 72-hour fever cycles and generally mild course [2]D. | Low prevalence; associated with nephrotic syndrome. |
| Zoonotic Knowlesi | Caused by P. knowlesi; rapid replication cycles (24h) leading to high parasitemia [94]D. | Primarily Southeast Asia (Malaysia). |
Red Flags
Certain clinical findings necessitate immediate escalation to intensive care and intravenous (2.4 mg/kg) [97]D.
- Respiratory Distress: Often termed "acidotic breathing" (Kussmaul respiration), this indicates deep metabolic acidosis or (ARDS) [42]D. Respiratory rate > 30/min or SpO2 < 92% are critical markers. In severe cases, FVC < 15 mL/kg may necessitate mechanical ventilation.
- Metabolic Instability: Blood glucose < 40 mg/dL (hypoglycemia) is a major predictor of mortality, especially in children [84].
- Renal Failure: Malaria-associated acute kidney injury (MAKI) is defined by a Creatinine > 3 mg/dL or oliguria. MAKI is a key driver of mortality and may progress to chronic kidney disease [81][93]D.
- Hyperparasitemia: A parasite density > 5-10% (or >250,000/μL) is associated with a high risk of clinical deterioration [85].
Atypical Presentations
- Asymptomatic Persistence: In low-transmission settings, individuals may carry P. falciparum for months without symptoms. This persistence is linked to elevated plasma taurine levels, which may modulate pathogenicity [103]D.
- HRP2-Negative Strains: Some parasites lack the pfhrp2 gene, leading to false-negative rapid diagnostic tests (RDTs). These patients may present with severe disease despite a negative screening test [100]D.
- Imported Malaria in Non-Immune Travelers: Travelers often present with more severe symptoms at lower parasitemia levels compared to residents of endemic areas due to a lack of partial immunity [98]D.
| Criterion | Threshold/Finding |
|---|---|
| Impaired Consciousness | GCS < 11 (adults) or BCS ≤ 2 (children) |
| Severe Anemia | Hemoglobin < 5 g/dL or Hematocrit < 15% |
| Acute Kidney Injury | Serum creatinine > 3 mg/dL (265 μmol/L) |
| Hypoglycemia | Blood glucose < 40 mg/dL (2.2 mmol/L) |
| Hyperlactatemia | Plasma lactate > 5 mmol/L |
| Jaundice | Bilirubin > 3 mg/dL with parasitemia > 100,000/μL |
Diagnosis and Workup
- ▸Microscopy remains the gold standard but significantly underestimates submicroscopic parasite reservoirs compared to PCR [117].
- ▸RDTs targeting HRP2 may yield false positives for weeks post-treatment, whereas pLDH-based tests correlate better with active infection [114], [121].
- ▸G6PD status must be quantitatively or qualitatively assessed using POC devices like the STANDARD G6PD Biosensor before using 8-aminoquinolines [106].
The diagnosis of malaria requires a high index of clinical suspicion followed by parasitological confirmation. Clinical diagnosis based solely on symptoms is increasingly discouraged due to the lack of specificity and the risk of mismanaging other febrile illnesses, such as (TBRF), which can mimic malaria and is often only identified incidentally during blood smear examination [108]D. The World Health Organization's "Test, Treat, and Track" initiative emphasizes that every suspected case must be confirmed by either light microscopy or a rapid diagnostic test (RDT) before initiating therapy [121]D.
Diagnostic Criteria
Formal diagnosis is established by the presence of Plasmodium parasites or antigens in the blood of a symptomatic patient.
- Required Features: Presence of fever (or history of fever) and a positive parasitological test (microscopy, RDT, or PCR) [114]D, [121]D.
- Supportive Features: Residing in or recent travel to an endemic area, anemia, thrombocytopenia, and splenomegaly. In children, coinfections with helminths (e.g., Schistosoma) are common and may alter the clinical presentation [24], [113]D.
- Exclusion Criteria: A single negative test does not exclude malaria if clinical suspicion is high; parasites may be sequestered or below the limit of detection during the initial presentation [117]D.
Laboratory Tests
Light Microscopy (Gold Standard)
Microscopy remains the definitive diagnostic tool. It allows for the identification of the Plasmodium species, quantification of parasite density, and monitoring of treatment response [115]D.
- Thick Smear: Used for screening. It concentrates the blood, allowing for the detection of low levels of parasitemia. Sensitivity is approximately 50–100 parasites/µL.
- Thin Smear: Used for speciation. It preserves the morphology of the red blood cells and the parasites, which is critical for distinguishing between P. falciparum, P. vivax, P. ovale, and P. malariae [32]D.
- Timing: Blood should be collected at the time of presentation. If the initial smear is negative but suspicion remains, repeat smears every 6–12 hours for 48 hours are indicated, as parasitemia can fluctuate [117]D.
Rapid Diagnostic Tests (RDTs)
RDTs are immunochromatographic assays that detect specific parasite antigens. They are essential in resource-limited settings where microscopy is unavailable [116]D.
- HRP2: Detects Histidine-Rich Protein 2, which is specific to P. falciparum. It can remain positive for several weeks after successful treatment due to antigen persistence [121]D.
- pLDH: Detects parasite Lactate Dehydrogenase, which is produced by all four major human species (pan-specific). It only detects viable parasites, making it useful for monitoring treatment [114]D.
- Limitations: Sensitivity may fail in cases of HRP2 gene deletions or low parasite density. Some lots of Abbott-Bioline™ RDTs have shown sensitivity failures as high as 18% in certain regions [123]D.
Nucleic Acid Amplification Tests (PCR)
PCR is the most sensitive method, capable of detecting <5 parasites/µL. It is primarily used for identifying submicroscopic reservoirs in the community [117]D, confirming species in zoonotic infections like P. knowlesi [115]D, and distinguishing recrudescence from new infection in clinical trials [110]D.
G6PD Testing
Before administering oxidative drugs (like primaquine or tafenoquine), patients must be screened for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency to prevent acute hemolytic anemia [106].
- Point-of-Care (POC) Devices: The STANDARD G6PD Biosensor and CareStart G6PD RDT are used to assess activity levels against the gold standard of spectrophotometry [106].
- Thresholds: A threshold of 30% activity is typically used to define deficiency, while 70% is used to identify intermediate status in females [106].
Imaging
Imaging is not used to diagnose malaria itself but to evaluate complications of severe malaria [84].
- Chest X-ray: Indicated if the patient develops respiratory distress to evaluate for pulmonary edema or ARDS.
- Brain MRI/CT: May be used in cases of cerebral malaria to exclude other causes of encephalopathy or to detect cerebral edema, though findings are often non-specific.
Electrodiagnostic Studies
Electrodiagnostic studies (NCS/EMG) are not part of the standard workup for acute malaria. They are reserved for patients who develop persistent neurological deficits or symmetrical weakness during recovery, which may suggest post-malarial neurological syndrome or a secondary inflammatory polyneuropathy.
Diagnostic Algorithm
- Step 1: Clinical Assessment: Evaluate for fever, travel history, and signs of severe disease (altered consciousness, jaundice, respiratory distress) [84].
- Step 2: Primary Testing: Perform a rapid diagnostic test (RDT) and/or thick and thin blood smears immediately [121]D.
- Step 3: Interpretation and Speciation: If positive, determine the species and parasite density. If P. knowlesi is suspected (e.g., in Southeast Asia), use PCR for confirmation as it is often misidentified as P. falciparum or P. malariae by microscopy [115]D.
- Step 4: Complication Screening: For confirmed cases, order a CBC (to check for anemia/thrombocytopenia), blood glucose, and renal/liver function tests [107]D.
- Step 5: Pre-treatment Screening: Perform G6PD testing if radical cure for P. vivax or P. ovale is planned [106].
| Test | Target/Finding | Timing | Sensitivity | Specificity |
|---|---|---|---|---|
| Thick Smear | Whole parasites (concentrated) | Immediate | ~50-100 parasites/µL | High |
| Thin Smear | Parasite morphology/Speciation | Immediate | Lower than thick | Very High |
| RDT (HRP2) | P. falciparum antigen | 15–20 mins | High (>90% at >200p/µL) | Variable (antigen persistence) |
| RDT (pLDH) | Pan-species enzyme | 15–20 mins | Moderate | High (active infection only) |
| PCR | Parasite DNA/RNA | Hours to days | <5 parasites/µL | Excellent |
| G6PD Biosensor | Enzyme activity units (U/g Hb) | 10 mins | High for <30% activity | High |
Management of Malaria
- ▸Intravenous artesunate (2.4 mg/kg) is the gold standard for severe malaria, significantly reducing mortality compared to older agents.
- ▸Radical cure for P. vivax requires primaquine, but its efficacy is contingent on the patient's CYP2D6 metabolic activity score.
- ▸Artemisinin-based combination therapies (ACTs) must be used to treat uncomplicated malaria to delay the spread of pfk13-mediated resistance.
The of malaria requires a rapid, stratified approach based on disease severity, infecting species, and regional resistance patterns [130][133]D. The primary goal is the rapid elimination of the asexual blood-stage parasite to prevent progression to severe disease and death, while secondary goals include the elimination of latent liver stages (hypnozoites) in P. vivax and P. ovale infections to prevent relapse [27][92]C. Current strategies are increasingly challenged by the emergence of artemisinin partial resistance (ART-R), characterized by delayed parasite clearance and mutations in the pfk13 gene [130][134]D.
Step 1: Initial Assessment and Severity Classification
Immediate triage is essential to distinguish between uncomplicated and severe malaria. Patients must be assessed for clinical danger signs, including impaired consciousness (cerebral malaria), respiratory distress, severe anemia, or renal impairment [89][92]C.
- Severe Malaria Criteria: Presence of P. falciparum (or occasionally P. vivax) parasitemia plus one or more complications: Glasgow Coma Scale <11, hemoglobin <7 g/dL, or serum creatinine >265 μmol/L [89][92]C.
- Disposition: Patients with severe malaria require immediate admission to an Intensive Care Unit (ICU) or high-dependency unit for parenteral therapy [84][89]. Children and non-immune travelers are at the highest risk for rapid deterioration [98]D.
- Special Populations: Pregnant women require integrated care to manage multi-morbidity, as malaria significantly increases maternal and infant mortality [139]D.
Step 2: Management of Uncomplicated Malaria
Artemisinin-based Combination Therapy (ACT) is the first-line treatment for uncomplicated P. falciparum malaria [133]D[141]D. ACTs utilize the rapid action of artemisinin derivatives to reduce the parasite biomass by approximately 10,000-fold per cycle, paired with a longer-acting partner drug to eliminate residual parasites [138]D[143]D.
- First-line Regimen: Artemether-lumefantrine (AL) (e.g., 20/120 mg tablets, weight-based dosing twice daily for 3 days) or Artesunate-sulfadoxine-pyrimethamine (AS+SP) [134]D[141]D.
- Mechanism of Action: Artemisinins induce widespread protein damage, which triggers the parasite's 26S proteasome for degradation; inhibitors of this proteasome have shown synergy with artemisinins [143]D.
- Emerging Alternatives: In areas with high resistance, triple combinations such as Fosmidomycin (30 mg/kg) + Clindamycin (10 mg/kg) + Artesunate are being evaluated to ensure efficacy [127].
Step 3: Management of Severe Malaria
Severe malaria is a medical emergency. Parenteral treatment should be initiated immediately upon suspicion, even before parasitological confirmation if delays are expected [84][92]C.
- Drug of Choice: Intravenous (IV) Artesunate 2.4 mg/kg at 0, 12, and 24 hours, then daily until the patient can tolerate oral medication [89][92]C.
- Reasoning: IV artesunate is superior to quinine in reducing mortality and has a better safety profile, though clinicians must monitor for delayed post-artesunate [89].
- Transition: Once the patient can swallow, complete a full 3-day course of an oral ACT [92]C.
Step 4: Radical Cure and Relapse Prevention
For P. vivax and P. ovale, eliminating the blood-stage infection is insufficient. Latent hypnozoites in the liver must be eradicated to prevent relapses [27].
- Protocol: Administer Primaquine 0.25–0.5 mg/kg daily for 14 days [27][92]C.
- Clinical Reasoning: Primaquine efficacy is highly dependent on host metabolism. Patients with reduced CYP2D6 activity (Activity Score <1.0) have a significantly higher risk of treatment failure and relapse because they cannot effectively convert primaquine into its active metabolites [27].
- Warning: G6PD testing is mandatory before primaquine administration to avoid severe hemolysis.
Step 5: Monitoring and Resistance Surveillance
Treatment success must be confirmed through clinical and parasitological follow-up.
- Day 3 Monitoring: The presence of parasitemia 72 hours after starting ACT (Day 3) is a hallmark of artemisinin partial resistance [133]D[134]D.
- Molecular Markers: Surveillance should track mutations in pfk13 (artemisinin), dhfr/dhps (antifolates), and pfcrt (chloroquine) [130][141]D[144]D. For instance, the dhfr triple mutant N51I/C59R/S108N is now nearly fixed in many regions, rendering older drugs like pyrimethamine ineffective [134]D[146]D.
Treatment Failure Protocol
If first-line ACT fails (defined as recurrence of symptoms and parasitemia within 28–42 days):
- Verify Adherence: Confirm the patient completed the full course and did not vomit the dose.
- Switch ACT: Use an alternative ACT with a different partner drug (e.g., switch from AL to Dihydroartemisinin-piperaquine) [133]D.
- Escalation: In cases of multi-drug resistance, consider experimental protocols or novel agents like PfDHODH inhibitors or 3-hydroxypropanamidines if available through clinical trials [122]D[145]D.
What NOT to Do
- Do NOT use monotherapy: Using artemisinins or partner drugs alone rapidly accelerates the selection of resistant strains [130][133]D.
- Do NOT ignore drug-drug interactions: 4-aminoquinolines (like chloroquine) can antagonize artemisinin action by blocking heme iron reactivity, particularly during the early ring stage of the parasite cycle [138]D.
- Do NOT delay parenteral therapy: In severe malaria, oral medication is unreliable due to potential vomiting and impaired absorption [84].
| Drug | Standard Dose | Route | Indication | Key ADR / Considerations | Evidence Level |
|---|---|---|---|---|---|
| Artesunate | 2.4 mg/kg | IV | Severe Malaria | Delayed hemolysis; superior to quinine | 1b [89][92]C |
| Artemether-Lumefantrine | 20/120 mg (weight-based) | Oral | Uncomplicated P. falciparum | Must be taken with fatty food for absorption | 1b [134]D[141]D |
| Primaquine | 0.25-0.5 mg/kg | Oral | Radical cure (P. vivax/ovale) | Hemolysis in G6PD deficiency; requires CYP2D6 | 2b [27][92]C |
| Fosmidomycin | 30 mg/kg | Oral | Uncomplicated (Combination) | Used with clindamycin/artesunate in resistance | 1b [127] |
| LAFIS10 | 15-125 mg/kg | IP (Exp) | Experimental | Piperazine derivative; nanomolar potency in vitro | 5 [148]D |
Supportive Care and Complication Management
- ▸Aggressive dual antipyretic therapy with Acetaminophen (15 mg/kg) and Ibuprofen (10 mg/kg) is superior to monotherapy for temperature control in CNS malaria [153].
- ▸Fluid resuscitation must be cautious; while balanced crystalloids and saline are comparable in mortality, over-hydration risks exacerbating cerebral edema in CM [151, 160].
- ▸Survivors of cerebral malaria and severe malarial anemia require long-term neurodevelopmental monitoring due to significant risks of cognitive impairment [175].
The of severe malaria, primarily caused by Plasmodium falciparum, requires a dual approach: rapid parasiticidal therapy and intensive supportive care to address multi-organ dysfunction [160]D[171]D. The "24, 2 Hours Initiative" emphasizes that uncomplicated cases must receive treatment within 24 hours, while severe cases require injectable therapy and supportive care within 2 hours of facility arrival to reduce mortality [159]D. Supportive care focuses on maintaining fluid homeostasis without exacerbating cerebral edema, controlling seizures, and managing acute kidney injury (AKI) [160]D[171]D.
Step 1: Initial Assessment and Severity Classification
Immediate triage must identify signs of severe malaria, including impaired consciousness (Glasgow Coma Scale < 11 or Blantyre Coma Scale ≤ 2), respiratory distress, or repeated seizures [157][160]D. Patients with these features require admission to an Intensive Care Unit (ICU) or a high-dependency unit [171]D.
- Mild/Moderate: Patients able to tolerate oral intake without signs of organ dysfunction [162]D.
- Severe: Characterized by cerebral malaria (CM), severe anemia (hemoglobin < 5 g/dL), AKI, or metabolic acidosis (pH < 7.3 or bicarbonate < 15 mmol/L) [160]D[171]D.
Step 2: Fluid Resuscitation and Hemodynamic Support
Fluid management in severe malaria is a delicate balance between correcting hypovolemia and avoiding fluid overload, which can precipitate pulmonary edema or increased intracranial pressure (ICP) [160]D.
- Fluid Choice: Administer Balanced Crystalloids (e.g., Lactated Ringer's) or 0.9% Normal Saline. A meta-analysis of 12 trials (n=3526) found no significant difference in mortality between balanced crystalloids and normal saline in children with severe infection, including malaria [151].
- Dosing: For patients in shock, provide a controlled bolus of 10-20 mL/kg. In the absence of shock, maintain fluid at 3-4 mL/kg/hr to ensure adequate renal perfusion while monitoring for signs of volume overload [151][160]D.
- Rationale: Restricted fluid strategies are often preferred in CM because parasitized erythrocyte sequestration and blood-brain barrier disruption increase the risk of cerebral edema [160]D[170]D.
Step 3: Seizure Control and Antipyretic Therapy
Seizures occur in up to 80% of children with CM and are a major risk factor for long-term neurological sequelae [153][169]D.
- Antipyretics: Administer aggressive antipyretic therapy with Acetaminophen 15 mg/kg every 6 hours combined with Ibuprofen 10 mg/kg every 8 hours [153]. A randomized trial demonstrated that this combination significantly reduces maximum temperature (Tmax) compared to acetaminophen alone, potentially protecting the brain from thermal injury [153].
- Anticonvulsants: For active seizures, use Diazepam 0.3 mg/kg IV or Midazolam 0.1 mg/kg IV/IM. If seizures persist, escalate to Phenobarbital 20 mg/kg IV [173]D.
- Monitoring: Be vigilant for nonconvulsive status epilepticus (NCSE), which may present as persistent coma or subtle psychiatric symptoms and requires EEG for diagnosis [168]C.
Step 4: Management of Acute Kidney Injury (AKI) and Acidosis
AKI is a common complication, particularly in CNS malaria, and is associated with high mortality [156].
- Thresholds: Monitor serum creatinine and urine output. Risk factors for AKI include high quantitative parasite counts and elevated histidine-rich protein 2 (HRP2) [156].
- Intervention: Maintain strict fluid balance. If the patient remains oliguric despite adequate resuscitation, initiate renal replacement therapy (RRT) early [171]D.
- Acidosis: Correct severe metabolic acidosis by optimizing oxygenation and perfusion. Bicarbonate is generally avoided unless pH < 6.9 due to the risk of paradoxical intracellular acidosis [171]D.
Step 5: Monitoring, Resolution, and Post-Discharge Care
Patients must be monitored for secondary complications, including stroke (ischemic or hemorrhagic) [161]D and movement disorders such as , which occurs in 52% of post-malarial movement disorder cases [150].
- Resolution Criteria: Parasite clearance, restoration of consciousness, and ability to tolerate oral medications [162]D.
- Post-Discharge: Survivors of severe malaria, particularly CM and severe malarial anemia (SMA), are at high risk for long-term cognitive impairment and re-hospitalization [158][175]D. Early childhood intervention programs, such as the "Baby Ubuntu" model, are recommended to support developmental milestones in survivors [86].
| Drug | Dose | Route | Indication | Key ADR | Evidence Level |
|---|---|---|---|---|---|
| Acetaminophen | 15 mg/kg q6h | PO/PR | Fever/CNS Malaria | Hepatotoxicity | 1b [153] |
| Ibuprofen | 10 mg/kg q8h | PO | Fever/CNS Malaria | Gastritis, AKI risk | 1b [153] |
| Diazepam | 0.3 mg/kg | IV | Acute Seizure | Respiratory depression | 2a [173]D |
| Artesunate | 2.4 mg/kg | IV | Severe Malaria | Delayed hemolysis | 5 [171]D |
| Phenobarbital | 20 mg/kg | IV | Refractory Seizure | Sedation, Hypotension | 5 [173]D |
Prevention and Screening
- ▸Chlorfenapyr-pyrethroid nets are the preferred intervention in areas with documented pyrethroid resistance to maintain vector control efficacy [177].
- ▸Folic acid supplementation in pregnant women should not exceed 1.0 mg/day when using antifolate antimalarials for IPTp to avoid reducing drug efficacy [91].
- ▸Ivermectin mass drug administration (iMDA) can reduce community malaria incidence by 26% by targeting mosquitoes during blood-feeding [128].
Malaria prevention requires a multi-tiered strategy that integrates vector control, chemoprevention, and vaccination to address the complex life cycle of and other species [184]D. As insecticide and drug resistance evolve, prevention protocols must adapt to local epidemiological data and climate-driven transmission patterns [186]D[196]D.
Vector Control Strategies
Vector control remains the primary defense against malaria transmission. Traditional long-lasting insecticidal nets (LLINs) rely on pyrethroids; however, widespread resistance among Anopheles mosquitoes has significantly reduced their entomological efficacy [178].
- Next-Generation Insecticide-Treated Nets (ITNs): The World Health Organization (WHO) now recommends chlorfenapyr-pyrethroid combination nets in areas where pyrethroid resistance is documented [177]. These nets consistently outperform pyrethroid-only nets by utilizing dual mechanisms of action to bypass metabolic resistance [177].
- Indoor Residual Spraying (IRS): IRS is a highly effective method for reducing mosquito density within households. New active ingredients, such as broflanilide (e.g., VECTRON™ T500), have been launched to provide long-lasting efficacy against resistant populations [194]D.
- Housing Modifications: Structural improvements to dwellings are recognized as critical supplementary strategies. These include screening windows and doors, sealing eaves to prevent mosquito entry, and installing insecticide-treated barriers [183]D.
- Ivermectin Mass Drug Administration (iMDA): Delivering ivermectin (e.g., once monthly for 3 months) to the general population can reduce malaria incidence by approximately 26% [128]. This approach targets the vector during the blood-feeding stage, making it a potent tool for reducing residual transmission [128].
Chemoprevention Protocols
Chemoprevention involves the administration of antimalarial drugs to at-risk populations to prevent infection or clinical disease.
Seasonal Malaria Chemoprevention (SMC)
SMC is the intermittent administration of full treatment courses of sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) during the high-transmission season [193]D. It is primarily targeted at children aged 3 to 59 months [193]D.
Protocol for SMC Implementation:
- Timing: Initiate at the start of the rainy season, typically for 3 to 4 cycles at monthly intervals [195]D.
- Dosing: Administer SPAQ according to age-based weight tiers. In some high-risk settings, SMC may be extended to children up to 15 years of age [195]D.
- Monitoring: Surveillance for adverse drug reactions (ADRs) is essential, as SPAQ can cause distress or, rarely, more serious reactions [193]D.
- Resistance Screening: Monitor for mutations in the pfdhfr and pfdhps genes (e.g., the A581G mutation), which can reduce the efficacy of the sulfadoxine-pyrimethamine component [188]D[191]D.
Intermittent Preventive Treatment in Pregnancy (IPTp)
IPTp with sulfadoxine-pyrimethamine (SP) is the standard of care for pregnant women in endemic regions [192]D. However, coverage remains suboptimal due to socio-economic barriers and increasing parasite resistance [192]D[200]D. A critical consideration in this population is folic acid supplementation; while 400 μg/day is standard for neural tube defect prevention, doses exceeding the tolerable upper intake level (>1.0 mg/day) may interfere with the efficacy of antifolate antimalarials like SP [91].
Vaccination
The introduction of the RTS,S/AS01 and R21/Matrix-M vaccines represents a landmark in malaria prevention. These vaccines target the pre-erythrocytic stage of the parasite [131].
- R21/Matrix-M: This vaccine has shown high efficacy in pediatric populations. Research indicates that a delayed fractional booster (e.g., at 6 months rather than monthly) may enhance memory B cell responses [131].
- Implementation: Countries like Cameroon have successfully integrated malaria vaccines into routine immunization schedules, achieving high reporting completeness [189]D.
- Future Targets: Research is ongoing into liver-stage antigens such as Pv_LISP-2 for and PfCSP combined with novel adjuvants to achieve sterile immunity [180]D[181]D.
Screening and Surveillance
Effective prevention requires robust screening and early warning systems to identify potential outbreaks, particularly those driven by climate variability [186]D.
- Climate-Based Surveillance: Integrating rainfall and flooding data (e.g., from the Tropical Rainfall Measuring Mission) allows health authorities to predict outbreaks and deploy mobile health teams to remote areas [195]D[196]D.
- Molecular Screening: Routine molecular surveillance of pfk13 (artemisinin resistance) and pfmdr1 markers is necessary to guide national treatment and prevention policies [191]D.
- Asymptomatic Reservoirs: In areas moving toward elimination, screening must account for asymptomatic reservoirs of non-falciparum species like P. malariae and P. ovale, which may persist despite standard interventions [32]D.
| Strategy | Target Population | Primary Agent/Tool | Key Consideration |
|---|---|---|---|
| ITNs | General Population | Chlorfenapyr-pyrethroid | Essential where pyrethroid resistance is high [177] |
| SMC | Children 3–59 months | SPAQ | Requires monitoring for pfdhps mutations [188]D[193]D |
| IPTp | Pregnant Women | Sulfadoxine-pyrimethamine | Avoid folic acid >1.0 mg/day [91][192]D |
| Vaccination | Infants/Children | R21/Matrix-M | Delayed boosters may improve B cell response [131] |
| iMDA | Community-wide | Ivermectin | Reduces residual transmission by 26% [128] |
References
- [1]
Bonacolta AM, Li L, Del Campo J et al.. “Endosymbiotic Apicomplexans of Marine Holobionts: Microbial Parasites in a Warming Ocean.” Integrative and comparative biology (2026). PMID: 41665867 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [2]
Nguyễn ĐTD, Lê HG, Võ TC et al.. “Genetic polymorphism and natural selection of apical membrane antigen-1 in Plasmodium malariae isolated from Vietnam.” BMC infectious diseases (2026). PMID: 41776459 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Clinical Features and Variants - [3]
Voges K, Dias GR, Dupim EG et al.. “Anopheles (Kerteszia) cruzii, the main malaria vector in the Brazilian Atlantic Forest, is a complex of at least five cryptic species.” Communications biology (2026). PMID: 41741717 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [4]
Lawal MS, Hayashida K, Sugi T et al.. “Detection of novel Pegivirus C genome in an unexplained febrile outbreak, Gombe State, Nigeria, 2024 by enhanced mNGS approach.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41667020 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, History and Physical Examination - [5]
Rubio-Palis Y, Corredor-Medina C, Lenhart AE et al.. “Anopheles species complexes from Guyana and Venezuela malaria endemic areas using COI sequences.” Malaria journal (2026). PMID: 41547760 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [6]
Rattanapitoon NK, Gordon CN, Charoenphon N et al.. “CXCL10high Microglia in Cerebral Malaria: Toward Translational Validation.” CNS neuroscience & therapeutics (2026). PMID: 41518083 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [7]
Daniyan MO, Singh H, Blatch GL. “Plasmodium knowlesi Heat Shock Protein 90s: In Silico Analysis Reveals Unique Druggable Structural Features.” International journal of molecular sciences (2025). PMID: 41465491 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [8]
Traoré H, Gnambani EJ, Hien DFS et al.. “Molecular characterization of potential Plasmodium-Blocking Serratia spp. bacteria in field-caught malaria mosquito in Burkina Faso.” Parasites & vectors (2025). PMID: 41423613 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [9]
Jote K, Gebrehiwot Y, Abebe A et al.. “Preliminary analysis of the conserved Plasmodium falciparum k13 gene in Arbaminch and Mirab Abaya, Ethiopia.” Malaria journal (2025). PMID: 41331631 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [10]
Hossain MS, Anjum MF, Rabbani MA et al.. “Bacillus altitudinis: a sustainable mosquito controlling biopesticide isolated from the rhizospheric soil of Nypa fruticans in mangrove forest.” BMC microbiology (2025). PMID: 41225312 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [11]
Pacheco MA, Miller EA, Harl J et al.. “Haemoproteus syrnii and other haemosporidians infecting owls from North America.” Malaria journal (2025). PMID: 41163075 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [12]
Dharmayanthi AB, Pratama R, Sánchez KL et al.. “The mitochondrial genome sequence of the Bornean orang-utan (Pongo pygmaeus) malaria parasite, Plasmodium pitheci.” Malaria journal (2025). PMID: 41063129 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Wandera HT, Nattoh G, Kiboi D et al.. “Investigation of prevalence and phylogenetic classification of Microsporidia MB and insecticide target site insensitivity resistance mutations in Anopheles gambiae s.l. and Anopheles funestus mosquitoes from Busia, Kenya.” BMC microbiology (2025). PMID: 41039202 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [14]
Pusawang K, Zhong D, Sriwichai P et al.. “Genetic variation in olfactory pathways associated with host-seeking behavior in natural populations of Anopheles minimus, a primary malaria vector in western Thailand.” Parasites & vectors (2025). PMID: 40993777 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [15]
Teixeira KS, Moreira HM, Roca TP et al.. “Reemergence of Oropouche in the Brazilian Amazon: A phylodynamic and phylogenetic analysis.” Travel medicine and infectious disease (2025). PMID: 40716624 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [16]
Bouyssou I, Golassa L, Vigan-Womas I et al.. “Genomic analysis of Plasmodium vivax field isolates circulating in sub-Saharan Africa.” Communications biology (2025). PMID: 40624365 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [17]
Usmani S, Gebhardt ME, Simubali L et al.. “Phylogenetic taxonomy of the Zambian Anopheles coustani group using a mitogenomics approach.” Malaria journal (2025). PMID: 40597261 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [18]
Kimita G, Collins J, Mutai B et al.. “Detection of zika virus disease caused by the Asian lineage of the zika virus at Kenya's Lamu island.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40010630 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [19]
Postigo-Hidalgo I, Magassouba N, Krüger N et al.. “Elucidating Infectious Causes of Fever of Unknown Origin: A Laboratory-Based Observational Study of Patients with Suspected Ebola Virus Disease, Guinea, 2014.” The Journal of infectious diseases (2025). PMID: 39928049 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Bodawatta KH, Albrecht T, Krausová S et al.. “Cophylogeny, narrow host breadth and local conditions drive highly specialized bird-haemosporidian associations in West-Central African sky islands.” Proceedings. Biological sciences (2025). PMID: 39837510 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Manu GP, Bonney JHK, Bawa FK et al.. “Reduced COVID-19 severity in Africa: a systematic review of host genetic and immunological responses to SARS-CoV-2 infection.” Frontiers in immunology (2026). PMID: 41993206 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [22]
Wilczyńska W, Akilimali A, Korzeniewski K. “Human Filariasis in Africa (2000-2025): Changing epidemiology, uneven diagnostic progress, and persistent neglect.” PLoS neglected tropical diseases (2026). PMID: 41945600 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [23]
Sadhewa A, Panggalo LV, Nanine I et al.. “G6PD deficiency in Indonesia: a systematic review and update of prevalence and variant maps in the context of malaria elimination.” The Lancet regional health. Western Pacific (2026). PMID: 41953713 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [24]
Hassan U, Siddiqa A, Zhu Y et al.. “Prevalence of Plasmodium falciparum coinfection with Schistosoma haematobium and Schistosoma mansoni among children in sub-Saharan Africa: a systematic review and meta-analysis.” Malaria journal (2026). PMID: 41935296 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Clinical Features and Variants, Diagnosis and Workup - [25]
Penjor K, Thapa B, Tsheten T et al.. “Estimating the burden of imported malaria in the Asia Pacific Region: A Systematic review and meta-analysis.” Journal of travel medicine (2026). PMID: 41934231 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [26]
Ramadan S, Talkhan A, Mansour A et al.. “Efficacy of ivermectin for malaria vector control: a systematic review and meta-analysis of randomized clinical trials.” Malaria journal (2026). PMID: 41917922 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [27]
Corder RM, Puça MCSB, Prete CA et al.. “Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.” PLoS neglected tropical diseases (2026). PMID: 41894411 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Management - [28]
Diallo EM, Loum MA, Diallo OO et al.. “Model-Based Assessment of the Effects of Selective Free Healthcare and Differentiated Diagnosis on Malaria Burden in the Republic of Guinea.” Tropical medicine & international health : TM & IH (2026). PMID: 41994979 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Management - [29]
Peng PY, Xu L, Duan HY et al.. “One health perspectives on the epidemiological features and changing incidence of natural focus and vector-borne infectious diseases in China: An observational trend study.” One health (Amsterdam, Netherlands) (2026). PMID: 41993771 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [30]
Rahman MS, Shiddik MAB, Chowdhury AH. “Spatiotemporal patterns of climate-sensitive vector-borne diseases in Bangladesh: leveraging machine learning and spatial regression for intervention strategies.” BMC medicine (2026). PMID: 41975424 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [31]
Barrow A, Barrow S, Bah Y. “Integrated housing quality and insecticide-treated net use: propensity score methods for childhood anemia prevention in The Gambia.” Malaria journal (2026). PMID: 41975408 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [32]
Rios-Teran CA, Tiedje KE, Bangre O et al.. “The dynamics of asymptomatic Plasmodium spp. infections following 10 years of malaria control interventions in Northern Sahelian Ghana.” PLoS neglected tropical diseases (2026). PMID: 41973755 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prevention and Screening - [33]
Smith SR, Nakibuuka V, Frick KD et al.. “Oxygen blenders for prevention of retinopathy of prematurity are highly cost-effective in Uganda.” Frontiers in medicine (2026). PMID: 41970396 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [34]
Zafindraibe NJ, Razafindrakoto AC, Zemey CB et al.. “Prevalence of malaria during pregnancy and coverage of intermittent preventive treatment with sulfadoxine-pyrimethamine in urban Amboasary-Sud, Southern Madagascar.” Malaria journal (2026). PMID: 41965694 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [35]
Addis GT, Addis MT, Mihret Y et al.. “"Referral patterns and associated factors among adult patients admitted with Severe Malaria at Shedeho Meket Primary Hospital, Northeast Ethiopia".” BMC infectious diseases (2026). PMID: 41963834 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features and Variants - [36]
Jaramillo-Underwood A, Ogunniyi A, Zhou H et al.. “Risk factors and geospatial associations with Plasmodium falciparum malaria infection and IgG seroprevalence: Nigeria, 2018.” The Journal of infectious diseases (2026). PMID: 41960779 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [37]
Matamanda SH, Musakwa W, Dzomba A. “Malaria at the margins: climatic extremes, migration, and urban informal settlement risk in South Africa.” Malaria journal (2026). PMID: 41952191 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [38]
Ilunga J, Mulenga-Cilundika P, Ekofo J et al.. “Barriers to integration of passive screening for sleeping sickness in Bibanga Health District, Democratic Republic of the Congo.” PLoS neglected tropical diseases (2026). PMID: 41950271 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [39]
Nguyen-Tien T, Tran V, Nguyen TM et al.. “Malaria situation in a highly endemic province in the Central Highlands of Vietnam: a retrospective analysis.” Malaria journal (2026). PMID: 41947165 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [40]
Sekitoleko I, Komata R, Ssali I et al.. “Early-life infectious and nutritional exposures and cardiovascular risk in early adulthood in Uganda: protocol for a new round of data collection in the Entebbe Mother and Baby Study birth cohort at 21 years (EMaBS@21).” BMJ open (2026). PMID: 41946545 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [41]
Belay A, Semahegn A, Hailu BT et al.. “Integration of population-based surveys for neglected tropical diseases: A scoping review.” PLoS neglected tropical diseases (2026). PMID: 41941535 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [42]
Wynkoop HJ, Lintner-Rivera M, Taylor T et al.. “Malarial pneumonopathy in Malawian children with cerebral malaria.” Malaria journal (2026). PMID: 41935286 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Clinical Features and Variants - [43]
Monteiro GM, Aïkpon RY, Dandonougbo C et al.. “Identification of malaria hotspots in southwestern Benin through spatial joint modelling of malaria incidence and vector abundance.” Malaria journal (2026). PMID: 41935258 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [44]
Tadesse S, Korma W, Sherfa A et al.. “Fatal and non-fatal health outcomes of malaria among reproductive age women in Eastern Sub-Saharan Africa, from 1990 to 2023.” Malaria journal (2026). PMID: 41933334 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [45]
Bennett A, Cotter C, Zarlinda I et al.. “Adapting reactive case detection strategies for high-risk populations to increase malaria infection detection in Aceh Province, Indonesia.” PLOS global public health (2026). PMID: 41931566 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [46]
Odibo EO, Nmorsi OPG, Egwunyenga OA et al.. “Haematological responses in children under 5 years with malaria and soil-transmitted helminth coinfections in Delta State, Nigeria: a cross-sectional study.” Therapeutic advances in infectious disease (2026). PMID: 41929652 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [47]
Tsigie M, Baldor L, Feufack-Donfack LB et al.. “Genetic variation in the Duffy blood group among vivax malaria patients and its impact on disease susceptibility.” Malaria journal (2026). PMID: 41928206 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [48]
Yitageasu G, Demoze L. “Spatial epidemiology of malaria by bed net utilization in 19 sub-Saharan African countries: a DHS-based study (2013-2023).” Malaria journal (2026). PMID: 41923227 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [49]
Ladan SM, Lima NP, Orimadegun AE et al.. “Prevalence and inequalities of missed opportunities for intermittent preventive therapy (IPTp) of malaria among pregnant women: an analysis of 2018 Nigeria DHS.” Malaria journal (2026). PMID: 41918116 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [50]
Odongo W, Seffren V, Obiet K et al.. “Community health volunteers improve access to malaria case management in Siaya County, Kenya.” Malaria journal (2026). PMID: 41917974 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [51]
Stephenson KB, Greenfeld A, Ryan MG et al.. “Egg supplementation for 24 weeks does not improve linear growth or reduce small intestinal permeability in Sierra Leonean children with moderate wasting: a randomized, blinded, controlled trial.” The American journal of clinical nutrition (2025). PMID: 41193034 ↗
L1bRCTCited in: History and Physical Examination - [52]
Sié A, Ouattara M, Bountogo M et al.. “Mass Azithromycin Distribution and Cause-Specific Mortality among Children Ages 1-59 Months Old: A Secondary Analysis of a Cluster-Randomized Controlled Trial.” The American journal of tropical medicine and hygiene (2026). PMID: 41252743 ↗
L1bRCTCited in: History and Physical Examination - [53]
Saady M, Ewaisha R, Azzazy HME. “Regional burden of undifferentiated fever and leading infectious etiologies of acute febrile illness in low- and middle-income countries: a meta-analysis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41161530 ↗
L2aSR_OBSCited in: History and Physical Examination - [54]
Chitrapady S, Rajendran R, K H et al.. “Machine-learning-based artificial intelligence tools for the diagnosis of tropical fevers: a systematic review and meta-analysis protocol of diagnostic test accuracy.” BMJ open (2025). PMID: 40854843 ↗
L2aSR_OBSCited in: History and Physical Examination - [55]
Anselmo A, D'Ugo E, Corrent L et al.. “A case of Human Pegivirus acute febrile infection diagnosed by Next Generation Sequencing (NGS).” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41638349 ↗
L4CASE_REPORTCited in: History and Physical Examination - [56]
Sous M, Boti M, Mose B et al.. “Reversible paralysis in pregnancy, thinking beyond malaria: a case report.” BMC infectious diseases (2025). PMID: 41286642 ↗
L4CASE_REPORTCited in: History and Physical Examination - [57]
Srirama S, Sihag KK, Chandrasekaran AK et al.. “Acute undifferentiated febrile illness in a traveler returning from Burkina Faso, West Africa to Puducherry, India- a case report.” BMC infectious diseases (2025). PMID: 40646441 ↗
L4CASE_REPORTCited in: History and Physical Examination - [58]
Batra P, Kaushik D, Rasane P et al.. “Early-Life Protein Nutrition and Enzymatic Regulation: Mechanistic Pathways Linking Growth Faltering, Stunting, and Obesity.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 41933918 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [59]
Abraham P, Lubis IND, Novivanti R et al.. “The household economic burden of human-only and zoonotic malaria, compared to other causes of acute febrile illness in Indonesia.” BMJ global health (2026). PMID: 41887663 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup - [60]
Sambe BS, Diagne A, Diatta AS et al.. “Malaria misdiagnosis among febrile patients in Senegal: implications for the underestimation of Plasmodium species diversity and malaria burden.” Malaria journal (2026). PMID: 41794727 ↗
L5OTHERCited in: History and Physical Examination - [61]
Moutombi Ditombi BC, Fritz M, Kombila Koumavor CA et al.. “Molecular evidence of co-circulation of different dengue virus serotypes associated with malaria co-infection among febrile children in Libreville, Gabon.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41722758 ↗
L5OTHERCited in: History and Physical Examination - [62]
Lo TQ, Edu-Quansah EP, Dogba J et al.. “Acute febrile illness surveillance using TaqMan Array Cards in two urban health facilities, Monrovia, Liberia, December 2018-March 2020.” PLoS neglected tropical diseases (2026). PMID: 41662363 ↗
L5OTHERCited in: History and Physical Examination - [63]
Arsuaga M, Oliveira-Souto I, Sánchez-Montalvá A et al.. “Travel health risks in adults over 60 years of age: insights from the +Redivi network in Spain.” Journal of travel medicine (2026). PMID: 41614979 ↗
L5OTHERCited in: History and Physical Examination - [64]
Merritt C, Vincenz C, Dolo Z et al.. “Association between placental malaria, postnatal linear growth, and body mass index in the Dogon Longitudinal Study, Mali.” Malaria journal (2026). PMID: 41501807 ↗
L5OTHERCited in: History and Physical Examination - [65]
Chitrapady S, Rajendran R, Haritha K et al.. “Development and evaluation of a diagnostic aiding tool for differentiating tropical fevers using artificial intelligence approach: a study protocol from tertiary care hospital in South India.” BMJ open (2026). PMID: 41490850 ↗
L5OTHERCited in: History and Physical Examination - [66]
Legesse F, Berhane N. “Prevalence of malaria and diagnostic performance of malaria rapid diagnostic tests compared to microscopy among febrile patients at Pawe General Hospital, Northwest Ethiopia.” BMC infectious diseases (2025). PMID: 41449340 ↗
L5OTHERCited in: History and Physical Examination - [67]
Remppis J, Weitz R, Aasi M et al.. “Child health in international travel: A German airport survey.” Travel medicine and infectious disease (2026). PMID: 41386402 ↗
L5OTHERCited in: History and Physical Examination - [68]
Lambebo IH, Eba K, Tucho GT. “Association between climatic conditions and infectious diseases: implications for Central Ethiopia region.” BMC infectious diseases (2025). PMID: 41331557 ↗
L5OTHERCited in: History and Physical Examination - [69]
Hedible KGB, Sawadogo AG, Zair Z et al.. “Care management and determinants of day 14 mortality in severely ill children aged under 5 years subsequent to hypoxaemia diagnosed using routine pulse oximetry in primary care: evidence from the AIRE project.” BMJ global health (2025). PMID: 41309154 ↗
L5OTHERCited in: History and Physical Examination - [70]
Tariq H, Alamgir A, Punar Z et al.. “Climate variability and infectious disease burden in Coastal Sindh, Pakistan: A trend analysis (2019-2022).” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41285193 ↗
L5OTHERCited in: History and Physical Examination - [71]
Kim JH, Chebu P, Fayomade R et al.. “Multi-Pathogen Surveillance of Acute Febrile Illness in Nigeria Using TaqMan Array Cards: Implementation Successes and Lessons Learned From the SAFIAN Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41263690 ↗
L5OTHERCited in: History and Physical Examination - [72]
Quiner CA, Ephraim AZ, Kwaghe V et al.. “Epidemiology of Plasmodium spp. Detection Among Acute Febrile Illness Patients in Two Regions of Nigeria.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41263689 ↗
L5OTHERCited in: History and Physical Examination - [73]
Erameh C, Courtney LP, Kwaghe V et al.. “High Burden of Coinfections With Epidemic-Prone Pathogens Among Febrile Patients in Nigeria: A Multi-Pathogen Surveillance Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 41263686 ↗
L5OTHERCited in: History and Physical Examination - [74]
Hedrich N, Lovey T, Bernhard J et al.. “Real-time illness monitoring in travellers: an international, prospective, digital surveillance study.” Travel medicine and infectious disease (2025). PMID: 41260318 ↗
L5OTHERCited in: History and Physical Examination - [75]
Tiberti N, Bertoli G, Mazzi C et al.. “Profiling of circulating immune factors and host-derived extracellular vesicles in response to bacterial or malaria acute fever.” Infection (2026). PMID: 41258581 ↗
L5OTHERCited in: History and Physical Examination - [76]
Abubakr M, Mohamed NS, Sami H et al.. “Epidemiological trends of malaria in Sennar State, Sudan.” Malaria journal (2025). PMID: 41214714 ↗
L5OTHERCited in: History and Physical Examination - [77]
Kaba S, Diallo MDD, Winner MBF. “Influence of community norms on caregivers' early care-seeking behaviour for under-5 children with fever in Guinea, a secondary analysis study.” Malaria journal (2025). PMID: 41084008 ↗
L5OTHERCited in: History and Physical Examination - [78]
Colubri A, Willing N, Grozdani A et al.. “Travel Healthy, a mobile app for participatory surveillance among U.S. international travelers.” Travel medicine and infectious disease (2025). PMID: 41083032 ↗
L5OTHERCited in: History and Physical Examination - [79]
Akanbi DO, Abaye BB, Averhoff F et al.. “Detection of dengue, malaria, and additional causes of acute febrile illness: The need for expanded testing, Bayelsa State, Nigeria.” PLoS neglected tropical diseases (2025). PMID: 41071829 ↗
L5OTHERCited in: History and Physical Examination - [80]
Amoadu M, Alhassan A, Odoom E. “Delay in malaria care-seeking for children under five in Africa: a systematic review.” Malaria journal (2026). PMID: 41845404 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [81]
Meena P, Singla V, Deshpande A et al.. “Clinical characteristics and outcome of malaria-associated acute kidney injury in adult patients: a systematic review and meta analysis.” Malaria journal (2026). PMID: 41620769 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [82]
Okek EJ, Jehopio J, Sande OJ et al.. “Progression from uncomplicated to severe malaria among children in settings receiving different combinations of malaria control interventions in sub-Saharan Africa: a systematic review and meta-analysis.” Tropical medicine and health (2026). PMID: 41862968 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [83]
Riggle BA, Chamzas A, Gopalakrishnan M et al.. “Safety, tolerability, and pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian adults with and without malaria: a Phase I dose-escalation clinical trial.” The Journal of infectious diseases (2026). PMID: 41748157 ↗
L2bTRIAL_NONRANDOMCited in: Clinical Features and Variants - [84]
Animut A, Bekana T, Siraj SZ et al.. “Treatment outcome and associated factors of severe malaria among admitted children in the Gambella Region, Southwest Ethiopia: a retrospective study design.” Malaria journal (2026). PMID: 41808107 ↗
L2bCOHORTCited in: Clinical Features and Variants, Diagnosis and Workup, Management - [85]
Noor M, Junaid M, Furqan A. “Burden of Plasmodium vivax and Plasmodium falciparum Malaria: clinical insights from a prospective study in Jacobabad, Sindh, Pakistan.” Malaria journal (2026). PMID: 41680751 ↗
L2bCOHORTCited in: Clinical Features and Variants - [86]
Scherer N, Nemerimana M, Nanyunja C et al.. “Early childhood intervention for children at risk of developmental disabilities and their caregivers in Rwanda: study protocol for the PDC/Baby Ubuntu cluster randomised trial.” Trials (2026). PMID: 41862972 ↗
L2bTRIAL_NONRANDOMCited in: Clinical Features and Variants, Diagnosis and Workup, Supportive Care and Complication Management - [87]
Wakai T, Chinedu S, Afolabi I. “Heme oxygenase-1 and malaria pathogenesis.” Frontiers in immunology (2026). PMID: 41836435 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [88]
Toure M, Keita S, Keita B et al.. “Trends in malaria indicators in urban and peri-urban areas of Bamako: a scoping review protocol.” Systematic reviews (2026). PMID: 41736077 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [89]
Cardona F, Héritier L, Cortaredona S et al.. “Assessment of Long-Term Sequelae After Severe Malaria: A Retrospective Study.” Pathogens (Basel, Switzerland) (2026). PMID: 41754407 ↗
L2bCOHORTCited in: Clinical Features and Variants, Management - [90]
Okullo AE, Ouma S, John CC et al.. “Prevalence and risk factors of gross neurologic deficits in children after severe malaria: A systematic review and meta-analysis.” PloS one (2026). PMID: 41843569 ↗
L2aSR_OBSCited in: Clinical Features and Variants - [91]
Qi YP, Crider KS, Gutman J et al.. “Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.” The Cochrane database of systematic reviews (2026). PMID: 41705996 ↗
L2aSR_OBSCited in: Clinical Features and Variants, Prevention and Screening - [92]
Sastre-Martínez AD, Gutiérrez MAG, Vallejo-Serna RA et al.. “Cerebral malaria caused by Plasmodium vivax in an afrodescendant adult in Colombia: case report.” Malaria journal (2026). PMID: 41851764 ↗
L4CASE_REPORTCited in: Clinical Features and Variants, Management, Supportive Care and Complication Management - [93]
Olwit G, Gutanamuka TB, Chris-Uchendu HC et al.. “Malaria-Associated Acute Kidney Injury: A Key Driver of Mortality in Endemic Regions.” International journal of nephrology and renovascular disease (2026). PMID: 41938719 ↗
L5REVIEW_NARRATIVECited in: Clinical Features and Variants - [94]
Nuin NA, Rajahram GS, Barber BE et al.. “G6PD variants but not Filipino beta-thalassemia are associated with reduced risk of Plasmodium knowlesi infection in Sabah, Malaysia.” Malaria journal (2026). PMID: 41987254 ↗
L5OTHERCited in: Clinical Features and Variants, Diagnosis and Workup - [95]
Lenz T, Sirel M, Hoppe H et al.. “Epigenetics and chromatin structure regulate var2csa expression and the placental-binding phenotype in Plasmodium falciparum.” eLife (2026). PMID: 41984626 ↗
L5OTHERCited in: Clinical Features and Variants - [96]
Klein SG, Mota KCP, Borges BC et al.. “Anti-GPI scFv as a Promising Tool for Intervention Against Cerebral Malaria in Mice.” International journal of molecular sciences (2026). PMID: 41977140 ↗
L5OTHERCited in: Clinical Features and Variants - [97]
Ravishankar K, Mace KE, Koiso S et al.. “Mapping Hospitals That Treat Severe Malaria Cases in the United States: Evidence to Inform Health Systems Strategies for Intravenous Artesunate Supply.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41955078 ↗
L5OTHERCited in: Clinical Features and Variants - [98]
Caiazzo R, Panero B, Carello M et al.. “Pediatric malaria in a non-endemic European setting: clinical patterns, laboratory markers, and the ambiguous role of immunity.” Infection (2026). PMID: 41935227 ↗
L5OTHERCited in: Clinical Features and Variants, Management - [99]
Kasprowicz D, Korzeniewski K, Wilczyńska W. “Clinical Characteristics and Outcomes of Hospitalized Malaria Patients in Rural Madagascar.” Journal of clinical medicine (2026). PMID: 41899312 ↗
L5OTHERCited in: Clinical Features and Variants, Supportive Care and Complication Management - [100]
Bendezu J, Larrauri-Aguilar P, Bautista R et al.. “Phenotypic and genotypic characterization of Plasmodium falciparum field isolates lacking pfhrp2 gene.” Malaria journal (2026). PMID: 41840576 ↗
L5OTHERCited in: Clinical Features and Variants - [101]
Figueroa-Downing D, Kelly SL, Cavelan A et al.. “Timing of the fourth dose of RTS,S/AS01 malaria vaccine in perennial settings: a modelling study.” Malaria journal (2026). PMID: 41827013 ↗
L5OTHERCited in: Clinical Features and Variants - [102]
Chelangat SC, Nakawuki A, Orech S et al.. “Facilitators and barriers to adherence to severe malaria treatment guidelines in children at Mbale Regional Referral Hospital, Uganda: a health workers' perspective.” Malaria journal (2026). PMID: 41749217 ↗
L5OTHERCited in: Clinical Features and Variants - [103]
Diffendall G, Millot P, Chen P et al.. “Longitudinal plasma metabolomics reveals a role for taurine in asymptomatic malaria and seasonal persistence.” Nature microbiology (2026). PMID: 41708949 ↗
L5OTHERCited in: Clinical Features and Variants - [104]
Boopathi PA, Singh S, Roy P et al.. “Comparative clinical transcriptome of pir genes in severe Plasmodium vivax malaria.” PLoS neglected tropical diseases (2026). PMID: 41706749 ↗
L5OTHERCited in: Clinical Features and Variants - [105]
Kanyamukenge DB, Maseko T, Khote FL et al.. “Young children with severe malaria in the Kapolowe health zone: an analysis of their parents' health-seeking behaviors and the challenges they face.” Malaria journal (2026). PMID: 41680770 ↗
L5OTHERCited in: Clinical Features and Variants - [106]
Unnikrishnan G, Singh A. “Diagnostic Accuracy of Point-of-Care Devices for Glucose-6-Phosphate Dehydrogenase Deficiency Detection Among Malaria Patients: A Systematic Review and Meta-Analysis.” Tropical medicine & international health : TM & IH (2026). PMID: 41774916 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [107]
Zambo Bitye BM, Mbianda Nana CM, Kwanou Tchakounte BD et al.. “cTfh Cell Activation and Changes in BTLA and LAG-3 Expression Differentially Associate With Poor Pregnancy Outcome in Plasmodium falciparum Placental Malaria.” Journal of immunology research (2026). PMID: 41983955 ↗
L5OTHERCited in: Diagnosis and Workup - [108]
Pavesi A, Ciccarone A, Logiudice J et al.. “Blood Smear Examination Matters: an Incidental Case of Tick-Borne Relapsing Fever in a Traveller Returning from Senegal.” Travel medicine and infectious disease (2026). PMID: 41974313 ↗
L5OTHERCited in: Diagnosis and Workup - [109]
Chen W, Ochomo E, Muok E et al.. “Modeling and Laboratory Experiments to Assess Detection of Plasmodium falciparum in Wastewater: Insights for Wastewater-Based Surveillance of Malaria.” Environmental science & technology (2026). PMID: 41964709 ↗
L5OTHERCited in: Diagnosis and Workup - [110]
Cavros I, Abanyie F, Kamara ARY et al.. “Efficacy and safety of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) for the treatment of uncomplicated Plasmodium falciparum malaria among children 6-59 months in three sentinel sites of Sierra Leone, 2021-2022.” Malaria journal (2026). PMID: 41957831 ↗
L5OTHERCited in: Diagnosis and Workup - [111]
Valkiūnas G, Iezhova TA, Chagas CRF et al.. “New experimental insights into the biology of avian malaria parasites.” Malaria journal (2026). PMID: 41952185 ↗
L5OTHERCited in: Diagnosis and Workup - [112]
Adeogun AO, Adetunji O, Babalola AS et al.. “Spatial eco-climatic gradients drive adaptive 2La chromosomal inversion polymorphism in Anopheles coluzzii, a major malaria vector in Nigeria.” International journal of health geographics (2026). PMID: 41943093 ↗
L5OTHERCited in: Diagnosis and Workup - [113]
Cuamba I, Santano R, Grau-Pujol B et al.. “Helminth coinfections mitigate clinical, parasitological, and immune outcomes in Mozambican children with malaria.” BMC medicine (2026). PMID: 41918093 ↗
L5OTHERCited in: Diagnosis and Workup - [114]
Shaba-Santu A, Moonga L, Ogata S et al.. “Prevalence and factors associated with malaria amongst under-five children in Senga Hill District, Northern Province, Zambia, a community-based cross-sectional study.” Malaria journal (2026). PMID: 41917959 ↗
L5OTHERCited in: Diagnosis and Workup - [115]
Maulana T, Marthoenis M, Almira CS et al.. “Socio-demographic characteristics and parasite density patterns of Plasmodium knowlesi Malaria in Aceh, Indonesia: insights from hospital-based data.” Infection (2026). PMID: 41913029 ↗
L5OTHERCited in: Diagnosis and Workup - [116]
Ahogni I, Avanon H, Hueha C et al.. “The accuracy of recording malaria rapid diagnostic test (RDT) results in public health facilities in Benin; results from the MaCRA project.” Malaria journal (2026). PMID: 41904563 ↗
L5OTHERCited in: Diagnosis and Workup - [117]
Jima B, Wondale B, Eligo N et al.. “Microscopy underestimates submicroscopic malaria infections in Ethiopia's southern rift valley: a community-based cross-sectional study.” Malaria journal (2026). PMID: 41904559 ↗
L5OTHERCited in: Diagnosis and Workup - [118]
Li F, Xu O, Zhou J et al.. “Functional characterization of AsOBP21f, an odorant-binding protein involved in human odor detection in the malaria vector Anopheles sinensis.” Parasites & vectors (2026). PMID: 41872964 ↗
L5OTHERCited in: Diagnosis and Workup - [119]
Carey-Ewend K, Shepard H, Yang G et al.. “Frequent Plasmodium ovale recurrence in coastal Tanzania.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41862423 ↗
L5OTHERCited in: Diagnosis and Workup - [120]
Matulis GA, Smith HP, Hall G et al.. “Characterization of arbovirus infections in patients within Haiti by screening discarded malaria rapid diagnostic test cassettes.” PLoS neglected tropical diseases (2026). PMID: 41860982 ↗
L5OTHERCited in: Diagnosis and Workup - [121]
Boadu S, Axame WK, Abanga WA et al.. “Evaluation of malaria rapid diagnostic test kit performance in a high-transmission setting: a facility-based cross-sectional study in rural Ghana.” Malaria journal (2026). PMID: 41857588 ↗
L5OTHERCited in: Diagnosis and Workup - [122]
Pippione AC, Villella N, Fornaseri F et al.. “Structure-based design of new pyrazole inhibitors targeting Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH).” European journal of medicinal chemistry (2026). PMID: 41855879 ↗
L5OTHERCited in: Diagnosis and Workup, Management, Prevention and Screening - [123]
Fenomanana J, Ravoavy A, Rakotoarisoa M et al.. “Field and laboratory evaluation of Abbott-Bioline™ Malaria Ag Pf/Pv RDT performance in a high-transmission setting: contrasting results with a low-endemic area.” Malaria journal (2026). PMID: 41851713 ↗
L5OTHERCited in: Diagnosis and Workup - [124]
Sarma K, Sarma H, Deka J. “Advancing global malaria control: therapeutic strategies, drug discovery, and formulation innovations.” Infection (2026). PMID: 41851575 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [125]
Duncombe CJ, Poehlman AS, Conrad EN et al.. “Host biological sex directs immune control of the Plasmodium parasite liver stage in mice.” Frontiers in immunology (2026). PMID: 41846936 ↗
L5OTHERCited in: Diagnosis and Workup - [126]
Mmweteni RE, Philbert AB, Mkandawile G et al.. “Detection of supergroup B Wolbachia strains and their co-infection with Plasmodium falciparum in wild Anopheles funestus in southeastern Tanzania: implications for malaria control.” Parasites & vectors (2026). PMID: 41845520 ↗
L5OTHERCited in: Diagnosis and Workup - [127]
Pfaffendorf C, Dejon-Agobé JC, Edoa JR et al.. “Population pharmacokinetics of fosmidomycin and clindamycin in combination with artesunate for uncomplicated Plasmodium falciparum malaria in Gabonese children and adults.” Malaria journal (2026). PMID: 41857641 ↗
L1bRCTCited in: Management - [128]
Xie K, Otuko R, Marathe A et al.. “Cost and cost-effectiveness of ivermectin mass drug administration for malaria control in Kwale county, Kenya: a modelling analysis of a cluster-randomised trial.” The Lancet. Global health (2026). PMID: 41713445 ↗
L1bRCTCited in: Management, Prevention and Screening - [129]
Ubalde J, Bradshaw C, Fatima SH et al.. “Systematic review of climate change interventions for improving child health.” BMJ paediatrics open (2026). PMID: 41856671 ↗
L2aSR_OBSCited in: Management - [130]
Habarugira F, Batamuriza J, Ndahimana R et al.. “The Global Landscape of Plasmodium falciparum Drug Resistance Markers, 2005-2025: A Systematic Review and Meta-Analysis.” Pathogens (Basel, Switzerland) (2026). PMID: 41754431 ↗
L2aSR_OBSCited in: Management - [131]
Bundi CK, Muñoz O, Kibwana E et al.. “B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.” Frontiers in immunology (2026). PMID: 41846927 ↗
L2bTRIAL_NONRANDOMCited in: Management, Prevention and Screening - [132]
Zhang X, Milligan P, Cheung YB. “Flexible and Interpretable Modeling of Overlapping Exposure Risks in Self-Controlled Case Series Analysis.” Statistics in medicine (2026). PMID: 41979390 ↗
L4CASE_REPORTCited in: Management, Prevention and Screening - [133]
Moriarty LF, Betoulle MM, Troell P et al.. “Antimalarial efficacy monitoring after nearly 20 years of artemisinin-based combination therapy in Africa: recalibrating guidance.” Trends in parasitology (2026). PMID: 41933996 ↗
L5REVIEW_NARRATIVECited in: Management - [134]
Niyomwungere D, Sinarinzi P, Caspar E et al.. “Border Region Surveillance of Malaria Drug Resistance, Northern Burundi, 2023-2024.” Emerging infectious diseases (2026). PMID: 41927306 ↗
L5OTHERCited in: Management - [135]
Ariefta NR, Beteck RM, Legoabe LJ et al.. “Synthetic quinolone-tethered aminoguanidine derivatives exhibit potent antiplasmodial activity.” International journal of antimicrobial agents (2026). PMID: 41921671 ↗
L5OTHERCited in: Management - [136]
Opperman D, Rabie T, Maré M et al.. “Protein Arginine Methyltransferase Inhibitors Target Multiple Stages of Plasmodium falciparum Parasites In Vitro.” ACS infectious diseases (2026). PMID: 41914674 ↗
L5OTHERCited in: Management - [137]
Wu L, Vllasaliu D, Mabayoje DA et al.. “Nanoscaffold-based 3D human liver spheroids for predictive hepatotoxicity screening of antimalarial compounds from the global health priority box.” Parasites & vectors (2026). PMID: 41872940 ↗
L5OTHERCited in: Management - [138]
Rosenthal M, Goldberg DE. “4-Aminoquinolines block heme iron reactivity and interfere with artemisinin action.” eLife (2026). PMID: 41870038 ↗
L5OTHERCited in: Management - [139]
Morgan CJ, Scoullar MJL, Melepia PU et al.. “Women's perspectives on health service integration for multi-morbidity in pregnancy, childbirth, and postpartum in a high-burden setting.” Med (New York, N.Y.) (2026). PMID: 41861824 ↗
L5OTHERCited in: Management - [140]
Aamir M, Rezaee K, Anari MS. “Intelligent in-silico prioritization of antimalarial peptide candidates under explicit physicochemical windows via de novo CTCM-Neo generation and conformal-gated calibrated classification.” Frontiers in cellular and infection microbiology (2026). PMID: 41859462 ↗
L5OTHERCited in: Management - [141]
Khilari A, Sharma S, Bajpai M et al.. “Targeted Genomic Surveillance Unveils Genetic Variations Linked to Regional Malaria Drug Resistance Dynamics in India.” Open forum infectious diseases (2026). PMID: 41846600 ↗
L5OTHERCited in: Management - [142]
Milić M, Obi P, Vanderwal CD et al.. “Polypharmacology in malaria treatment: single drugs, multiple mechanisms, greater impact.” Trends in parasitology (2026). PMID: 41846229 ↗
L5REVIEW_NARRATIVECited in: Management - [143]
Gonçalves AF, Lima-Pinheiro A, Sampaio-Marques B et al.. “Profiling 26S Proteasome Activity of Plasmodium falciparum Monitored by a Live-Cell Assay.” International journal of molecular sciences (2026). PMID: 41828333 ↗
L5OTHERCited in: Management - [144]
Salazar YEAR, Rezende AM, Puça MCSB et al.. “Emergence of artemisinin-based combination therapy resistance markers in Plasmodium falciparum from the Brazilian tri-border region of the Guiana Shield.” Antimicrobial agents and chemotherapy (2026). PMID: 41817181 ↗
L5OTHERCited in: Management - [145]
Moritz A, Hirn-Derksen B, Klein S et al.. “Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class.” Malaria journal (2026). PMID: 41808149 ↗
L5OTHERCited in: Management - [146]
Putaporntip C, Somkuna J, Rojrung R et al.. “Contrasting evolutionary trajectories of pyrimethamine resistance in human and zoonotic malaria parasites.” Malaria journal (2026). PMID: 41808095 ↗
L5OTHERCited in: Management - [147]
Vandy A, Turay BA, Lahai M et al.. “Herbal product use in urban slum communities of Freetown, Sierra Leone: Consumption patterns, predictors, and ethnomedicinal applications.” Journal of ethnobiology and ethnomedicine (2026). PMID: 41794856 ↗
L5OTHERCited in: Management - [148]
Abadia ACM, Diedrich D, Vieira LC et al.. “In Vivo Antimalarial Activity and Toxicological Profile of LAFIS10, a Piperazine Derivative From Ursolic Acid.” Tropical medicine & international health : TM & IH (2026). PMID: 41788057 ↗
L5OTHERCited in: Management - [149]
Alemayehu G, Awoke A, Kassa Z. “Ethnobotanical documentation and conservation assessment of medicinal plants used by the Somali community in Karamara forest patches, Eastern Ethiopia.” Journal of ethnobiology and ethnomedicine (2026). PMID: 41787442 ↗
L5OTHERCited in: Management - [150]
Garg RK, Pandey S, Mahdi RA et al.. “Spectrum of movement disorders in Malaria: a systematic review of case reports, case series, and cohort studies.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40537708 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [151]
Sankar J, Das RR, Banothu KK. “Fluid resuscitation in children with severe infection and septic shock: a systematic review and meta-analysis.” European journal of pediatrics (2024). PMID: 38916738 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [152]
Casey RM, Najjengo MS, Lubega I et al.. “Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.” Vaccine (2024). PMID: 39153293 ↗
L1bRCTCited in: Supportive Care and Complication Management - [153]
Birbeck GL, Seydel KB, Mwanza S et al.. “Acetaminophen and Ibuprofen in Pediatric Central Nervous System Malaria: A Randomized Clinical Trial.” JAMA neurology (2024). PMID: 38857015 ↗
L1bRCTCited in: Supportive Care and Complication Management - [154]
Taylor SM, Korwa S, Wu A et al.. “Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.” PLoS medicine (2022). PMID: 36215323 ↗
L1bRCTCited in: Supportive Care and Complication Management - [155]
Haine V, Oneko M, Debois M et al.. “Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study.” The Lancet. Global health (2025). PMID: 40288377 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [156]
Tembo D, Mwanza S, Mwaba C et al.. “Risk factors for acute kidney injury at presentation among children with CNS malaria: a case control study.” Malaria journal (2022). PMID: 36316704 ↗
L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management - [157]
Ray STJ, Fuller CE, Ahmadu A et al.. “Aetiologies, neuroradiological features, and risk factors for mortality and long-term neurosequelae of febrile coma in Malawian children: a prospective cohort study.” The Lancet. Global health (2025). PMID: 40280145 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [158]
Opoka RO, Namazzi R, Datta D et al.. “Severe falciparum malaria in young children is associated with an increased risk of post-discharge hospitalization: a prospective cohort study.” Malaria journal (2024). PMID: 39633351 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [159]
Ranjbar M, Katureebe C, Musanhu CC et al.. “The 24, 2 hours initiative: a game changer in malaria mortality reduction.” Malaria journal (2025). PMID: 41219920 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [160]
Vathi S, Corriero A, Rodríguez EE et al.. “Management and monitoring strategies for severe cerebral malaria: a guide for the intensivist.” Annals of intensive care (2025). PMID: 41060528 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [161]
Aderinto N, Abraham IC, Olatunji G et al.. “Stroke incidence, presentation, and outcomes in malaria: a review of current evidence.” Malaria journal (2025). PMID: 40533728 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [162]
Long B, MacDonald A, Liang SY et al.. “Malaria: A focused review for the emergency medicine clinician.” The American journal of emergency medicine (2024). PMID: 38096639 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [163]
Tolou-Ghamari Z. “A Review of the Association between Infections, Seizures, and Drugs.” Central nervous system agents in medicinal chemistry (2025). PMID: 38676494 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [164]
Deng S, Wang W, Lu W et al.. “Anti-NMDAR encephalitis following malaria: expanding the spectrum of post-malarial neurological syndromes.” Frontiers in immunology (2026). PMID: 41909705 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [165]
Kumar A, Agatrao BA, Prakash A et al.. “Malaria-associated splenic haemorrhage requiring emergency splenectomy: a rare complication managed in a resource-constrained setting.” Malaria journal (2026). PMID: 41787355 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [166]
Nayak B, Mohanty S, Das S et al.. “Radiological findings in fulminant cerebral malaria: a rare neuroimaging presentation.” Malaria journal (2025). PMID: 41423666 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [167]
Huang XA, Xiang R, Liao RH et al.. “Babesia microti (Babesiidae, Piroplasmida) infection in a Chinese traveler returning from the United States of America.” Infectious diseases of poverty (2025). PMID: 40490844 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [168]
Wu X, Qin N, Yi F et al.. “Cerebral malaria presenting as nonconvulsive status epilepticus: a case report.” Malaria journal (2024). PMID: 38500090 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [169]
Postels DG, Katangwe-Chirwa T. “Cerebral malaria.” Seminars in pediatric neurology (2025). PMID: 40701686 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [170]
Comino Garcia-Munoz A, Varlet I, Grau GE et al.. “Contribution of Magnetic Resonance Imaging Studies to the Understanding of Cerebral Malaria Pathogenesis.” Pathogens (Basel, Switzerland) (2024). PMID: 39770302 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [171]
Akafity G, Kumi N, Ashong J. “Diagnosis and management of malaria in the intensive care unit.” Journal of intensive medicine (2024). PMID: 38263976 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [172]
Toudou-Daouda M. “Epilepsy in Niger: An overview of the current situation.” Epilepsia open (2023). PMID: 37042866 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [173]
Yacubian EMT, Kakooza-Mwesige A, Singh G et al.. “Common infectious and parasitic diseases as a cause of seizures: geographic distribution and contribution to the burden of epilepsy.” Epileptic disorders : international epilepsy journal with videotape (2022). PMID: 36219093 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [174]
Fung JST, Hwang B, Dunsmuir D et al.. “A 2-Phase Survey to Assess a Facility's Readiness for Pediatric Essential Emergency and Critical Care in Resource-Limited Settings: A Literature Review and Survey Development.” Pediatric emergency care (2022). PMID: 35981329 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [175]
Bangirana P, Bond C, Namazzi R et al.. “Cerebral Malaria and Severe Malarial Anemia, but not Other Forms of Severe Malaria, Are Associated With Long-Term Cognitive Impairment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41631529 ↗
L5OTHERCited in: Supportive Care and Complication Management - [176]
Torres-Fernandez D, Dalsuco J, Garcia-Mauriño C et al.. “Epidemiology and Outcomes of Pediatric Fever in a Rural District of Southern Mozambique: 17 Years of Morbidity Surveillance.” Open forum infectious diseases (2025). PMID: 41394513 ↗
L5OTHERCited in: Supportive Care and Complication Management - [177]
John Mwang'onde B. “Chlorfenapyr-pyrethroid nets for pyrethroid-resistant malaria vectors: efficacy, resistance risks, and policy implications.” Global health action (2026). PMID: 41766494 ↗
L2aSR_OBSCited in: Prevention and Screening - [178]
Tungu PK, Sudi W, Batengana B et al.. “Efficacy of long-lasting insecticidal nets before and after the selection of pyrethroid-resistant Anopheles gambiae s.l. and Anopheles funestus s.l. in northeastern Tanzania: A longitudinal meta-analysis of experimental hut trials at a single location.” Parasites & vectors (2026). PMID: 41742175 ↗
L2aSR_OBSCited in: Prevention and Screening - [179]
Firdaus MH, Ho Imran DS, Puteh SEW et al.. “Strategic resource allocation for malaria elimination in endemic settings: a systematic review of cost-effectiveness evidence.” Frontiers in public health (2025). PMID: 41737900 ↗
L2aSR_OBSCited in: Prevention and Screening - [180]
Tandel N, Thakkar M, Ahuja M et al.. “Poly(I:C) and R848 adjuvants elicit sizeable humoral immunity to liver stage malaria antigens.” Frontiers in immunology (2026). PMID: 41983137 ↗
L5OTHERCited in: Prevention and Screening - [181]
Donassolo RA, Soares da Veiga GT, Nisimura LM et al.. “Naturally acquired antibodies to Plasmodium vivax Pv_LISP-2, a potential liver stage vaccine antigen.” Frontiers in immunology (2026). PMID: 41972120 ↗
L5OTHERCited in: Prevention and Screening - [182]
Su JS, Stover J, Pretorius C et al.. “The benefits of investments to combat HIV, tuberculosis, and malaria for primary healthcare from 2000 to 2023: An economic modeling analysis.” PLoS medicine (2026). PMID: 41950262 ↗
L5OTHERCited in: Prevention and Screening - [183]
Guido G, Totaro V, Lochoro P et al.. “Household and community-based approaches to malaria and cholera prevention: A narrative review with case studies from Uganda and Mozambique.” PLoS neglected tropical diseases (2026). PMID: 41941455 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [184]
Zhu Y, Wu S, Qi Y et al.. “Reinventing malaria control: hierarchical intervention strategies for African settings based on the microbiota-barrier-innate immunity axis.” Frontiers in immunology (2026). PMID: 41929484 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [185]
Traoré N, Zabré P, Millogo O et al.. “Assessing the role of interventions and climate on malaria mortality among children under five years of age: insights from two decades of data from the Health Demographic Surveillance System of Nouna, Burkina Faso.” Journal of global health (2026). PMID: 41926164 ↗
L5OTHERCited in: Prevention and Screening - [186]
Yahouedo AG, Merle CS, Diallo I et al.. “Climate change and malaria control in Africa: country experiences and strategic responses.” Malaria journal (2026). PMID: 41923083 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [187]
Diallo EM, Langlet A, Onyango LA et al.. “Healthcare providers' knowledge, perceptions and practices of malaria control strategies in the Republic of Guinea: insights from a qualitative study.” BMJ global health (2026). PMID: 41916616 ↗
L5OTHERCited in: Prevention and Screening - [188]
Diallo MA, Tine A, Sow D et al.. “Emergence of Plasmodium falciparum pfdhps A581G mutation in Southern Senegal under Seasonal Malaria Chemoprevention pressure, 2020-2023.” Communications medicine (2026). PMID: 41896338 ↗
L5OTHERCited in: Prevention and Screening - [189]
Josue Kedakse TSN, Kaba M, Baonga SF et al.. “Evaluation of the first malaria vaccine introduction: ongoing learning opportunities during the introduction into routine immunisation in Cameroon.” BMJ global health (2026). PMID: 41887666 ↗
L5OTHERCited in: Prevention and Screening - [190]
Lu S, Ding W, Huang L et al.. “The Institution-based Network on China-Africa Cooperation for Malaria Elimination: fostering a transcontinental hub for strengthening China-Africa cooperation on malaria control and elimination efforts.” Infectious diseases of poverty (2026). PMID: 41872959 ↗
L5OTHERCited in: Prevention and Screening - [191]
Mediavilla A, García X, Martínez-Vallejo P et al.. “Molecular markers of antimalarial drug resistance in pfk13, pfmdr1, pfdhfr, and pfdhps genes of Plasmodium falciparum in a rural municipality in Cubal, Benguela Province, Angola (2022-2023).” Malaria journal (2026). PMID: 41840616 ↗
L5OTHERCited in: Prevention and Screening - [192]
Audibert C, Borghini-Fuhrer I, El Gaaloul M et al.. “Improving malaria chemoprevention coverage in pregnancy: Surveying stakeholder preferences for new product profiles and community-delivery approaches across five African countries.” PLOS global public health (2026). PMID: 41824506 ↗
L5OTHERCited in: Prevention and Screening - [193]
Otoo BAF, Opoku-Mireku M, Seaneke SK et al.. “Incidence and trends of adverse drug reactions during seasonal malaria chemoprevention among children: evidence from Ghana's pharmacovigilance database, 2015-2023.” Malaria journal (2026). PMID: 41814293 ↗
L5OTHERCited in: Prevention and Screening - [194]
Ando Y, Mori K, Bradley J et al.. “Determination of the preliminary discriminating concentration of broflanilide against malaria vector mosquito Anopheles gambiae by multi-centre susceptibility testing.” Malaria journal (2026). PMID: 41803905 ↗
L5OTHERCited in: Prevention and Screening - [195]
Dolo AM, Cissoko M, Teme A et al.. “Extreme rainfall, flooding and malaria in the Sahara: outbreak analysis in Kidal, Mali 2024.” Malaria journal (2026). PMID: 41792755 ↗
L5OTHERCited in: Prevention and Screening - [196]
Lake MW, Asemahagn MA, Gelaye KA et al.. “Climate, environmental, and programmatic correlates of malaria resurgence in Amhara, Ethiopia (2018-2024): a Bayesian spatiotemporal analysis.” Malaria journal (2026). PMID: 41782025 ↗
L5OTHERCited in: Prevention and Screening - [197]
Begashaw DT, Alemayehu MA, Animut Y et al.. “Utilization and associated factors of long-lasting insecticide-treated nets among households in Gondar Zuria district, Northwest Ethiopia: a mixed methods study, 2025.” Malaria journal (2026). PMID: 41781949 ↗
L5OTHERCited in: Prevention and Screening - [198]
Rodrigues R, Dhatrak A, Bal M et al.. “Design of an implementation research study for a digital omnichannel community engagement and risk communication intervention for the prevention and control of vector-borne diseases in India: the OMNIVEC-India study protocol.” Frontiers in public health (2025). PMID: 41777371 ↗
L5OTHERCited in: Prevention and Screening - [199]
Laurenson AJ, Pierce BG, Takala-Harrison S et al.. “TEpiNom: A computational framework integrating population data to prioritize Plasmodium falciparum T cell epitopes.” Vaccine (2026). PMID: 41775037 ↗
L5OTHERCited in: Prevention and Screening - [200]
Atijosan A, Atijosan A, Salau AO. “Geospatial mapping of gender-sensitive malaria vulnerability and ITN usage barriers in Zamfara State, Nigeria.” Malaria journal (2026). PMID: 41772643 ↗
L5OTHERCited in: Prevention and Screening